Cell death plays a pivotal role in the maintenance of tissue homeostasis. Key players in the controlled induction of cell death are the Death Receptors (DR). CD95 is a prototypic DR activated by its cognate ligand CD95L triggering programmed cell death. As a consequence, alterations in the CD95/CD95L pathway have been involved in several disease conditions ranging from autoimmune diseases to inflammation and cancer. CD95L-induced cell death has multiple roles in the immune response since it constitutes one of the mechanisms by which cytotoxic lymphocytes kill their targets, but it is also involved in the process of turning off the immune response. Furthermore, beyond the canonical pro-death signals, CD95L, which can be membrane-bound or soluble, also induces non-apoptotic signaling that contributes to its tumor-promoting and pro-inflammatory roles. The intent of this review is to describe the role of CD95/CD95L in the pathophysiology of cancers, autoimmune diseases and chronic inflammation and to discuss recently patented and emerging therapeutic strategies that exploit/block the CD95/CD95L system in these diseases.

INTRODUCTION
The division, differentiation, and death of a cell are highly regulated events in every developing organism and, in the adult individual, the loss of single cells plays a primary role in the maintenance of tissue homeostasis. Cell death, considered as a physiological event, can be defined as a highly evolved and conserved cell elimination mechanism, which responds to homeostatic and morphogenetic stimuli. The cells have a genetically-encoded death program that is finely controlled at the transcriptional and post-transcriptional levels. The definition of “programmed or regulated cell death” (RCD) is appropriate for the description of this phenomenon. Amongst the different types of RCD [1], apoptosis remains the most studied. Two major apoptotic pathways have been described: the extrinsic pathway or Death Receptor (DR) pathway and the intrinsic or mitochondrial pathway, which are linked [2]. In both pathways, specific aspartyl cysteine proteases (caspases) are activated and cleave cellular substrates, ultimately leading to the disruption of multiple cellular processes and morphological changes, such as cell shrinkage or the formation of apoptotic bodies, typical of apoptosis. The crosstalk between the two apoptotic pathways is carried out by the fact that caspase-8, involved in the extrinsic pathway, is able to cleave BID, a Bcl-2 family protein involved in the intrinsic pathway, thus activating the latter after apoptotic stimulus via DR and eventually strengthening the apoptotic signal [3–5].

Molecular bases of apoptotic signaling
The intrinsic mitochondrial-mediated apoptotic pathway. The intrinsic or mitochondrial pathway can be triggered by a variety of cellular stressors (e.g. DNA-damaging agents, nutrient deprivation, hypoxia) and is tightly controlled by pro- and anti-apoptotic members of the Bcl-2 family of proteins. These cellular stress primarily lead to the increased transcription and/or post-translational activation of pro-apoptotic members of the Bcl-2 family of proteins [6, 7]. The key event of this intrinsic RCD is the mitochondrial outer membrane permeabilization (MOMP) induced by the oligomerization of the pro-apoptotic effector members of this family (BAX, BAK, and in some cases BOK) at the MOM [8]. MOMP allows the release of several caspase activators, such as the cytochrome c, from the mitochondrial intermembrane space to the cytosol. Hence, understanding the molecular bases of the pore-forming capacity of the effectors and of the regulation of their activation is crucial [8–11]. In the cytosol, cytochrome c promotes the assembly of a caspase activation platform called the apoptosome that also includes caspase-9, the activation factor of apoptotic proteases-1 (Apaf-1) and dATP [12]. Indeed, in the absence of apoptotic stimuli, Apaf-1 exists in an inactive monomeric conformation while it undergoes heptameric oligomerisation upon binding to cytochrome c and dATP in apoptotic conditions [13]. The formation of the apoptosome triggers the activation of caspase-9 which in turn activates the effector caspases-3, -7 that drive cell demise [14, 15]. MOMP also promotes the release of anti-apoptotic factors, such as the second mitochondrial activators of caspase (Smac/Diablo) and Omi/HtrA2 (high temperature requirement A2) and endonuclease G (EndoG) [16]. The protein Smac [17, 18] interacts with the BIR2 and BIR3 domains of the X-linked inhibitor of apoptosis protein (XIAP), neutralizing the inhibitory effect of XIAP on caspases-3, 7, and 9 [19]. Omi/HtrA2 [20–23] is a serine protease which, once released into the cytosol, is also able to significantly increase the activity of caspases by inhibiting XIAP. Noteworthy, MOMP can also induce non-apoptotic cell death such as ferroptosis, necroptosis and pyroptosis as recently reviewed elsewhere [7, 24].
The extent of MOMP largely defines the propensity of a cell to die or survive upon cell stress. The availability and activity of the different Bcl-2 family members influences the cellular readiness or “priming status” for MOMP. This priming status can be determined through BH3-profiling [25, 26] that evaluates MOMP upon incubation of permeabilized cells with BH3 peptides mimicking the action of some pro-apoptotic members of the Bcl-2 family. This assay has mainly been used to predict the sensitivity of cancer cells to various chemotherapeutic agents (resistant cells usually display lower priming) and to interrogate the sensitivity of cancer cells to the increasing arsenal of BH3-mimetics (molecules mimicking the activity of some pro-apoptotic Bcl-2 family members). MOMP is not necessarily a complete process. Indeed, partial MOMP has been observed when apoptotic induction is weak (minority MOMP) or accompanied by caspase inhibition (incomplete MOMP). The ability of cells to retain some non-permeabilized mitochondria, ATP synthesis and to eliminate damaged mitochondria influences their propensity to survive upon incomplete MOMP. Indeed, the remaining intact mitochondria can repopulate the whole mitochondrial pool [27, 28]. In the case of minority MOMP, caspase activation is insufficient to drive death but can promote DNA damage and genomic instability [29]. In addition, several reports indicate that MOMP can initiate multiple inflammatory signaling, for example the cGAS/STING [30, 31] or the NF-kB pathways [32]. Thereby MOMP can impact on the cell and its microenvironment beyond its ability to promote cell death.

Taken together, it appears that further understanding the mechanisms dictating the extent of MOMP, its ability to induce various types of cell death as well as non-death pathways in different pathophysiological contexts (e.g., upon pathogen infection, during tumor progression, etc.) and in different cell types will be required to fully expand the therapeutic targeting of the mitochondrial pathway. For further considerations on this topic, we advise readers to explore the many recent reviews available [7, 24, 33].

**CD95 and CD95L: main structural features.** The extrinsic apoptosis pathway takes its name from the extracellular signal molecules that bind to receptors exposed on the surface of target cells, leading to a different way of activating the apoptotic signal compared to the mitochondrial-mediated one. There is a family of receptors specialized in the transmission of the signal upon binding by their cognate ligand, which leads to the extrinsic programmed cell death: the DR. The DR belong to the Tumor Necrosis Factor Receptor (TNFR) superfamily, which counts a total of 29 receptors associated with a smaller selection of 19 ligands of the corresponding TNF ligands superfamily. CD95, TNFR1, DR3, DR4, DR5, and DR6 are the most studied DR that, upon ligand binding, convey death signal by using a conserved intracellular region of ~80 amino acids called the “Death Domain” (DD) [34]. This review particularly focuses on the DR CD95, its physiological ligand CD95L and the current approaches developed to therapeutically target this pair. CD95, encoded by the FAS gene, is a 319aa type I glycoprotein devoid of enzymatic activity that signals through protein-protein interaction. Mature CD95 is composed of three cysteine-rich extracellular domains, CRD3, CRD2, and CRD1 starting from the transmembrane domain and moving towards the N-Terminal. CRD2 and partly CRD3 are used for the recognition and binding of the ligand, while CRD1, comprising a subdomain called PLAD (Pre-Ligand Assembly Domain) [35, 36], is needed for the preassembly of CD95 in homodimeric or homotrimeric forms at the plasma membrane. The cytosolic region is composed of the previously mentioned Death Domain (DD) [34], which is essential for the transduction of the apoptotic signal, and a Membrane Proximal Domain (MPD) which conveys non-apoptotic signaling (Fig. 1) [37]. CD95L, encoded by the FASLG gene, consists of a total of 281aa, an extracellular region with a C-terminus and an intracellular region with an N-terminus. This protein is expressed at the plasma membrane in the form of a homotrimer thanks to the preassembly between monomers that takes place through an extracellular domain called TNF Homology Domain (THD) [38]. The THD also mediates receptor binding. The membrane-proximal extracellular stalk region is proteolytically processed by several metalloproteases to release soluble forms of CD95L (sCD95L), which generally display non-apoptotic activities (see part 2). The cytosolic region is then composed of an 80 amino acid tail containing a domain rich in proline, which is involved in the reverse signaling induced by CD95L-CD95 interaction in CD4 and CD8 T cells (Fig. 1). This reverse signaling involves the engagement of the TCR and co-stimulatory receptors along that of CD95/CD95L [39–42]. The reported outcomes of this reverse signaling depends on the cell type, with both proliferation and cell cycle arrest being reported, but the knowledge on this subject is still very partial.

**Molecular bases of CD95-induced apoptotic signaling.** CD95-mediated extrinsic apoptotic signaling begins with the binding of CD95L, via its THD on CRD2 and part of the CRD3 of CD95. In addition to the pre-association of CD95 mediated by the PLAD [35, 36], Fu et al. recently showed that proline motifs in the transmembrane (TM) domain also contribute to the trimerization of the receptor. Mutations of these motifs did not abrogate PLAD-mediated preassembly of unliganded CD95 but reduced CD95L-induced apoptosis, implying that these residues are important for stabilizing signaling-active CD95 oligomers [43]. Binding of CD95L has been proposed to trigger a reorganization of CD95 multimers and a conformational change in CD95 intracellular domain, allowing for the recruitment of the adaptor FADD (Fas-associated protein with Death Domain) to CD95 via DD-mediated homotypic interactions [44–47]. FADD is necessary for CD95L-induced apoptosis [48, 49]. In addition to its DD, FADD contains a Death Effector Domain and acts as a pivot for the assembly of Ded filaments which are chains of proteins formed through Ded-mediated interactions [50–52]. The Ded chains nucleate from FADD [51–54] and also comprise procaspase-8 and cellular FLICE-like inhibitory proteins (c-FLIP) which are both key players in the cell death network [51, 52]. Extensive work has been undertaken, mainly in the past 15 years, to understand the mode of assembly of these structures. Beyond CD95- and TRAIL-R1/2-associated complexes, similar structures likely also nucleate from other death-inducing complexes such as the Bax/Apaf-1/TNFSF10-TRAIL-induced complex II, as well as the panoptosome [53, 55–57] and could thus influence cell fate upon a plethora of signals. In the case of CD95 signaling, the complex formed by CD95, FADD, caspase-8 and cFLIP constitutes a platform for caspase-8 activation which was first called the DISC (for Death-Inducing Signaling Complex) [44]. Procaspase-8 contains two DEDs, Ded1, and Ded2, located at its N-terminus and C-terminal large (p18) and small (p10) catalytic subunits. As described below, the formation of the Ded filaments allows for the activation of caspase-8 which occurs via dimerization and a series of internal cleavages, leading to the separation of the tandem Ded from the catalytic subunits p18 and p10 [53, 54, 58–60]. The active p10 and p18 subunits are released into the cytoplasm to form mature active caspase-8 (Fig. 2). Fully matured caspase-8, an heterotetramer of two p18 and two p10, cleaves effector caspases-3, 6 and 7, which then cleave subcellular substrates, ultimately inducing cell death [61]. Three isofoms of cFLIP have been described: cFLIP long, short and related (cFLIPL, cFLIPs, and cFLIPa). cFLIPs and cFLIPa comprises solely two tandem Ded. In addition to the tandem Ded, cFLIPL comprises a small and a large caspase-like catalytically inactive subunit. The initial Ded-chain model, described by Inna Lavrik and Marion MacFarlane’s laboratories, proposed a nucleation of the chain from FADD involving an interaction between the Ded of
FADD with the DED1 of caspase-8, whilst further chain elongation implicated an interaction between the DED2 of FADD-associated caspase-8 with the DED1 of the incoming caspase-8, ultimately bringing the two catalytic domains of caspase-8 in close proximity [51, 52, 62, 63]. The molecular configuration of the DED filaments was further unveiled in 2016, by cryogenic electron microscopy (cryo-EM) analysis [53]. This study established that the orientation of the DED filaments actually relies on three different types of interactions (type I, II and III) between DEDs. Rather than a single linear chain nucleating from FADD through type I interactions, three strands of DED chains assemble via type II and III interactions to ultimately form a triple-helical structure [53, 54]. These different types of interactions define a hierarchy in the formation of the DED filaments, with FADD being rather poorly able to nucleate the DED of cFLIP, arguing against the theory of competition between procaspase-8 and c-FLIP for FADD. Thus, by affecting the conformation of caspase-8 and bringing in proximity the catalytic subunits of two procaspase-8, the DED-chain architecture works as a platform for the activation of this initiator caspase [64, 65].

With regard to cFLIP proteins, it was first thought that these act by competing with caspase-8 for FADD binding or by preventing FADD self-association, akin to the viral FLIP MC159 [65], but this view has been challenged. Multiple evidence now demonstrate that cFLIP<sub>S/R</sub> actually precludes caspase-8 activation within the DISC. Indeed, reports highlighted that cFLIP<sub>S/R</sub> could limit DED-chain elongation and that cFLIP<sub>S/R</sub> incorporation into DED filaments actively prevented the formation of inter-strand assembly of caspase-8 catalytic domains [54, 63, 65]. Contrary to the small cFLIP isoforms, cFLIP<sub>L</sub> has been reported to possess a dual function, promoting or limiting caspase-8 activation and apoptosis. This is likely due to the fact that the cFLIP<sub>L</sub>/caspase-8 heterodimer does possess a catalytic activity, albeit DISC restricted, and that cFLIP<sub>L</sub> does not limit but promotes DED elongation. Hence, depending on the relative cellular amount of cFLIP<sub>L</sub> to caspase-8, cFLIP<sub>L</sub> might either facilitate the formation of filaments, and thereby of apoptosis-inducing caspase-8 homodimers (low cFLIP<sub>L</sub> to caspase-8 ratio) or, on the contrary (high cFLIP<sub>L</sub> to caspase-8 ratio), mainly result in formation of cFLIP<sub>L</sub>/caspase-8 heterodimers which, whilst able to cleave local substrates (e.g RIPK1), do not mediate apoptosis [63, 66–70].

Another initiator caspase, caspase-10, can be recruited to the TRAIL-R1/2 and CD95 DISC [66, 71, 72]. The role of this caspase in apoptosis induction by CD95L and TRAIL, and in particular its ability to substitute to caspase-8 loss, has been controversial. Caspase-10 is conserved in multiple other vertebrates [73] but lost in certain rodents (mice and rats) which has limited the study of its

**Fig. 1** The CD95 receptor and its cognate ligand CD95L. Schematic representation of the functional domains of the CD95 Death Receptor (A) and its ligand CD95L in its membrane-bound form (B). (DD Death Domain, MPD Membrane Proximal Domain, CRD Cysteine-Rich Domain, PRD Proline-Rich Domain, THD TNF Homology Domain).
Caspase-8, in concert with cFLIPL, is able to cleave RIPK1, along with other key components of the necroptosis cascade, which limits necroptosis induction, as reviewed in [61]. The oligomerisation and auto-cleavage of procaspase-8 into its active form induces then the activation of the effector caspases-3, -6, -7 leading to apoptosis. Active caspase-8 is also able to cleave Bid, generating t-Bid that promotes Mitochondrial outer membrane permeabilization (MOMP) and thus the apoptosome-mediated effector caspase activation.

As mentioned above, caspase-8 also cleaves Bid, generating t-Bid that promotes MOMP and thus apoptosome-mediated effector caspase activation. Whether the engagement of the mitochondrial pathway downstream of CD95 is required for completion of apoptosis depends on the multiple variables described to influence DISC formation (e.g. expression level of the DISC components, local lipid composition of the plasma membrane, etc.) as well as downstream regulators of the apoptosis pathway such as XIAP [85–87]. The discovery that caspase-8 is essential during embryonic development lead to the identification of its role as a regulator of necroptosis. Indeed, caspase-8, in concert with cFLIP, is able to cleave RIP1, along with other key components of the necroptosis cascade, which limits necroptosis induction, as reviewed in [61]. In addition, as further developed later, several of the players of the apoptotic pathway, and in particular DISC components, are also involved in non-cytotoxic signaling outputs.

**IN VolveMent of CD95/CD95L in Cancer and Autoimmune Diseases**

**Cancer**

Multiple defects in the DR-mediated pathway have been observed in human tumors [88–91]. In healthy individuals, extrinsic apoptosis plays a central role in the immune-mediated elimination of infected or transformed cells. Therefore, defects in the extrinsic apoptotic pathway contribute to tumorigenesis primarily by limiting the efficiency of immune surveillance [92]. Cancer cells have different ways of escaping from apoptosis [93]. These include modification of the expression of pro- and anti-apoptotic proteins, such as inhibitors of apoptosis (IAPs) and the anti-apoptotic members of the Bcl-2 family among others, as well as the expression of CD95 itself at the membrane [94, 95]. Mutations in the FAS gene have been detected in both hematologic and solid tumor malignancies [96–99]. These mutations are mainly located in exon 8 and 9, which code for the DD, thus leading to resistance to CD95-mediated apoptosis [91, 93]. Accumulating evidence has shown that CD95 signaling cascades are often disrupted in several autoimmune diseases and malignant tumors [100–102], leading to the triggering of pro-tumorigenic cellular outcomes, rather than apoptosis [89, 103]. Considering the potential pro-tumorigenic effect of an incomplete induction of mitochondria-dependent death-signaling mentioned above, one could hypothesize that weak apoptotic signaling downstream of CD95 could also have tumor-promoting effects. Furthermore, the quality of cell death induced downstream of CD95 might also differentially impact on inflammation and tumor progression, even though this remains to be tested. In addition, several non-apoptotic pathways are also induced by CD95L, as detailed below, and contribute to its tumor-promoting and pro-inflammatory roles [88].

**Non-apoptotic CD95-mediated pathways (NF-κB, MAPK, PI3K/Akt)**

**NF-κB pathway.** Several studies reported that CD95-mediated stimulation can induce the apoptotic pathway in some cells, while in others, the non-apoptotic NF-κB (nuclear factor kappa B) pathway is favored [104, 105]. NF-κB is a transcription factor playing an important role in the inflammatory responses as well as in the regulation of cell survival, differentiation and proliferation. A non-optimal regulation of this signaling pathway has been associated with a high incidence of pathological conditions, such as cancer and chronic inflammation [106]. At the cell population level, the stimulation of CD95 by CD95L has long been reported to concomitantly induce apoptotic signaling and NF-κB activation.
NF-κB-induced cell death, thus activating the cell survival induced by the role for caspase-10 that would negatively regulate the caspase-8-induced NF-κB on the cell type [104, 109]. Recently, Horn et al. described a new RIPK1 in this process seems to be less pronounced and depends seem to be essential for NF-κB activation upon CD95L, the role of CD95 yet, it is tempting to speculate that NF-κB activation could also be ignited from the CD95 DISC, as recently shown for CD95L [110]. Experiments carried out inhibiting caspases prevented TRAIL/anti-APO-1-induced apoptosis, but not NF-κB activation, indicating that both pathways bifurcate upstream of caspase-8 full activation [112]. Furthermore, the ability of DR to induce NF-κB activation was drastically reduced in a FADD-deficient CD95L-expressing cell line (e.g., Jurkat cells) [112]. Caspase-8 participates in CD95L- and TRAIL-induced inflammatory signaling as a scaffold for assembly of a Caspase-8-FADD-RIPK1-containing complex, leading to NF-κB-dependent inflammation [109, 113]. Whilst this has not been studied for CD95 yet; it is tempting to speculate that NF-κB activation could also be ignited from the CD95 DISC, as recently shown for TRAIL [114]. Contrary to FADD and caspase-8 which seem to be essential for NF-κB activation upon CD95L, the role of RIPK1 in this process seems to be less pronounced and depends on the cell type [104, 109]. Recently, Horn et al. described a new role for caspase-10 that would negatively regulate the caspase-8-induced cell death, thus activating the cell survival induced by the NF-κB pathway [80]. TRADD, which is essential for the TNF-alpha-induced NF-κB activation, was not involved in the CD95L-induced NF-κB activation [110]. Experiments performed on cell lines resistant to CD95-mediated apoptosis, reported TRAF2 as a key player in pancreatic cancer pathophysiology [115]. This group also observed that the stimulation of TRAF2-overexpressing cells with CD95L led to induction of NF-κB, enhanced IL-8-secretion, and a further increased invasiveness. In fact, several E3 ligases contribute to NF-κB activation upon CD95 stimulation, namely cIAP1/2 and the Linear Ubiquitin chain Assembly Complex (LUBAC), likely in a manner similar to their roles in TNF and TRAIL-induced gene-activation [104, 114, 116]. Downstream of these different actors, the activation of NF-κB relies on IκBα degradation, the protein responsible for constitutively inhibiting NF-κB. In a manner similar to TNF and TRAIL signaling, it is likely that several components of the CD95 DISC and/or secondary complex modified with ubiquitin allow the recruitment and activation of the IKK complex and potentially the TAB/TAK1 complex. The IKK complex is composed of three subunits (i.e., IKKα, IKKβ, IKKγ). The IKKβ subunit can then phosphorylate IκBα, marking it for lysine-48 ubiquitination and degradation by the proteasome. This leads to the translocation of NF-κB into the nucleus which promotes the expression of multiple genes including pro-inflammatory cytokines as well as anti-apoptotic proteins, such as cIAP1, cIAP2, and XIAP (Fig. 3) [117, 118]. Moreover cFLIP can be upregulated in some cell lines under critical involvement of the NF-κB pathway [119, 120] also resulting in increased resistance to CD95L or TNF.

MAPK pathway. The MAPK family includes six main groups in humans, among which JNK (Jun N-terminal Kinase), ERK1/2 and the p38 isofrom must be mentioned for their involvement in CD95-mediated pro- and anti-apoptotic signaling pathways [121–123]. The induction of the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling pathway, which regulates growth, proliferation, differentiation, survival, innate immunity and cellular development is involved in tumorigenesis in multiple tumor types [124]. In the latent state, the inactive MAPKs are cytosolic. The activation of the different MAPKs takes place according to a common general scheme, which provides for a series of sequential phosphorylations catalyzed by...
different kinases activated in succession. MAPK is phosphorylated by a MAPK kinase (MKK), itself phosphorylated by a MAPK kinase kinase (MKKK), in turn activated by an activator protein.

CD95-mediated stimulation has been suggested early on to induce the JNK pathway through the DAXX adapter protein (Death domain associate protein 6), which after fixation with CD95-DD induces the apoptotic pathway [125, 126]. c-FLIP can block this pathway by inhibiting DAXX [127]. CD95-mediated JNK activation also appears to occur rather slowly, compared to other cell stress stimuli, such as inflammatory cytokines and oxidative stress [128]. Indeed, expression of cFLIP variants or use of different caspase inhibitors in primary human keratinocytes, blocked late death ligand-induced JNK or p38-MAPK activation, suggesting that these responses are secondary to caspase activation [129]. This may be due to the fact that caspase-3 can cleave and thereby activate the MAP3K MEKK1 [128]. Of note, the signal induced by soluble CD95L rather results in a rapid and transient phosphorylation of ERK1/2 [130]. This MAPK protein is widely involved in enhancing growth and proliferation upon CD95 activation [121]. Stimulation of CD95 on primary sensory neurons triggers neurite growth through sustained activation of the extracellular signal-regulated kinase (ERK) pathway and subsequent upregulation of p35, a neurite growth mediator [131]. Of note, in pancreatic apoptosis-resistant tumor cells, CD95L- and TRAIL-induced upregulation of pro-inflammatory genes was found to be partially dependent on the ERK signaling pathway via caspase-mediated activation [132]. The same group suggested that the stimulation of the ERK pathway must probably depend on a caspase-dependent factor operating downstream of the DISC complex. According to another group, CD95L can also induce the autocrine production of EGF (Epidermal Growth Factor Receptor) ligands and the consequent activation of EGFR followed by ERK1 and ERK2 mitogen-activated protein kinases [133]. In primary fetal astrocytes, blocking ERK phosphorylation with specific inhibitors resulted in a significant reduction of CD95-induced proliferation [134]. In this context, ERK phosphorylation is also caspase-dependent. Noteworthy, cFLIPL can also contribute to ERK activation. Indeed, caspase-8 can cleave cFLIPL into different cleavage products. One of these cleavage products is identified with the name of p43-FLIP [135], which associates with Raf-1 activating the phosphorylation cascade, leading to ERK activation and ultimately to ERK translocation into the nucleus, where it exerts proliferative or pro-inflammatory effects through downstream transcription factor targets (Fig. 3).

**PI3K pathway.** As mentioned previously, mCD95L has been cleaved by various metalloproteases to produce several soluble forms of the ligand, together referred here as sCD95L [136-140]. Soluble CD95L has been shown to be accumulated in the serum of patients suffering from various diseases [141, 142], whilst the exact cleavage form(s) accumulating in most of these cases remains to be determined. sCD95L was initially believed to be a competitor of its membrane-bound counterpart (mCD95L) in the interaction with CD95 and the consequent induction of the apoptotic signal. It is only in the last decade that it has been reported that not only sCD95L failed in the induction of programmed cell death [143, 144], but that its interaction with CD95 led to the induction of a different type of signal, including engagement of ERK, NF-kB, and PI3K/Akt [145, 146]. Gene-targeted mice selectively lacking either metalloprotease-dependent soluble CD95L (sCD95L) or membrane-bound CD95L (mCD95L) were generated [147]. Mice lacking sCD95L appeared normal and their T cells were able to kill target cells, whereas T cells lacking mCD95L could not kill cells through CD95 activation. Furthermore, mice lacking mCD95L displayed SLE-like symptoms and histiocytic sarcoma. Of note, one group has described that the stimulation of CD95 with sCD95L can induce a calcium-dependent process that leads to the activation of a c-yes/PLCγ1/PI3K/Akt pathway promoting Triple Negative Breast Cancer (TNBC) cell migration [141] (Fig. 3).

mCD95L has also been shown to activate the PI3K/Akt pathway. There appears to be a crosstalk between the two signaling paths PI3K and NF-kB under mCD95L stimulation. Indeed in mutant PIK3CA (PI3K alpha catalytic subunit), but not WT PIK3CA-expressing Hct116 cells, TRAIL, and CD95L stimulated NF-kB activation [148]. It is now clear that caspase-8 not only mediates the cell death signal initiated by CD95L, but also contributes to the induction of apoptosis-independent pathways, such as cell migration and adhesion. Caspase-8 was found to be a substrate of Src kinase c-yes [149]. It has been observed that the stimulation of motility through the EGF, first activates c-yes, and then triggers the phosphorylation of caspase-8 on Tyrosine-380 in the linker region between the two subunits (i.e., p18 and p10) of the procaspase-8 converting it from a pro-apoptotic factor to a cell motility factor. The Y380 phosphorylation prevented downstream activation of the caspase cascade proving a valuable path to explore for sensitization of CD95-resistant tumors to extrinsic apoptotic stimuli [150]. The catalytic domain of caspase-8 is in fact not required for the induction of the migration signal. Once phosphorylated, caspase-8 interacts with the p85 alpha subunit of PI3K (Fig. 3) [151].

In a mouse cell model of glioblastoma (GBM) the c-yes/PI3K-p85 interaction was reported to signal cell invasion via glycosyn synthesis kinase 3-beta pathway and subsequent expression of matrix metalloproteinsases [152]. Blockade of CD95-mediated activity in this cellular model drastically reduced the number of invading cells. In the same context CD95 expression associates with stemness and EMT features and poorer overall survival. CD95-mediated activation of the PI3K p85 also maintained the expression of EMT-related transcripts. The authors therefore suggested that CD95 would be a potential prognostic biomarker in GBM [153].

**Systemic autoimmune diseases**

To date, more than 80 diseases in which the etiology is certainly, or most likely, autoimmune have been described [154]. Around the 1960s/70s the distinction was made between systemic autoimmune diseases, with general signs and symptoms and the involvement of multiple organs and systems, and organ-specific autoimmune diseases, where the immunopathological damage is localized to an organ and the clinical picture closely linked to the dysfunction of the organ itself. The self and non-self recognition functions are carried out through an elaborate identification system that involves T and B lymphocytes. The central selection process eliminates the vast majority of auto-reactive lymphocytes at an immature stage during their development, through Bcl-2-interacting mediators of cell death, such as Bim [155]. However, despite the numerous central tolerance mechanisms, many mature B and T lymphocytes, generated in the central lymphoid organs, then reach the peripheral lymphoid organs and undergo activation, turning into their self-reactive form [156, 157]. The Bim-dependent apoptotic pathway is required both for the killing of self-reactive immature B and T lymphocytes during their development and for the elimination of auto-reactive mature B and T lymphocytes in peripheral lymphoid organs [158]. However, except in the thymus, most of the TCR-related mature T-cell apoptosis is induced by the extrinsic pathway via membrane DR, and in particular one of the most important elements of this regulation is apoptosis activated by the CD95/CD95L system [159]. The importance of CD95 and CD95L in eliminating activated T cells is underlined by the anomalies observed when mutations in the genes coding for CD95 or CD95L occur. The CD95/CD95L system has a dual role in immune regulation [160-163]. It constitutes one of the mechanisms by which cytotoxic lymphocytes kill the target, but is also involved in the process of turning off the response. Activation of the lymphocytes leads to an increase in CD95L expression and the ability to trigger apoptosis. Recently Heikenwälder's group...
recently been observed that said impaired apoptosis [175]. In ALPS patients lacking germline regard as several heterozygous due to mutations in another factor in the T-cell apoptosis pathway, [164]. The process could occur and damage other organs as well. This observation, made on a mouse model, could be useful for the design of future immunotherapies without affecting the antigen-specific T-cell immunity.

Peripheral T-cell CD95-induced apoptosis eliminates over-activated and self-reactive T cells via a mechanism called "Activation-Induced Cell Death" (AICD) [165]. T-cell activation is also associated with CD95L expression at the cell surface, thus representing a specific aspect of the immune system. AICD is induced through the interaction between CD95 and CD95L, both expressed on activated T cells surface [166]. Similarly to T cells, it has been reported that not only B cells are capable of expressing CD95L but that the level of CD95L expression correlates with the level of activity of B cells, thus making them capable of killing CD95 expressing cells [167]. Consequently, the abnormal activation of these CD95L-expressing B cells is implicated in the immune modulation of various diseases and thus constitutes a therapeutic target [168, 169]. The constitutive expression of CD95L in some "immunologically privileged" tissues (e.g., the Sertoli cells, the testes, or the anterior chamber of the eye), has suggested that CD95L plays also an important role in reducing the activity of immune cells in these tissues. Several studies exploring mutations in the genes encoding CD95 and CD95L have allowed to better understand the pathogenesis of autoimmune diseases, such as ALPS (Autoimmune Lymphoproliferative Syndromes) or SLE (Systemic Lupus Erythematosus).

**ALPS: Autoimmune lymphoproliferative syndromes.** Some FAS gene mutations impair the function of the molecule, leading either to a reduced expression on the membrane, or to the impairment of the ability to transmit the apoptotic signals [170]. The defective shutdown of the immune response resulting from the defective function of CD95 can be the cause of both the progressive accumulation of lymphocytes in the peripheral lymphatic organs and the development of autoimmune reactions [171]. The most common trigger of ALPS is due to autosomal dominant mutations of the FAS gene [172, 173], and, less frequently, of FASLG, the gene encoding the CD95 ligand [174]. Much less common forms of autoimmune lymphoproliferation are due to mutations in another factor in the T-cell apoptosis pathway, caspase-10. Controversial studies have been carried out in this regard as several heterozygous CASP10 variants have been identified along with variants known to be polymorphic. It has recently been observed that said CASP10 mutations are capable of impaired apoptosis [175]. In ALPS patients lacking germine mutations in FAS, some dominant somatic mutations in the DR and notably in the Death Domain were found. These somatic mutations were identified as missense variants likely to change the normal structure and impact the oligomerization and functionality of CD95 [176]. Of note, a large study in a cohort of 100 ALPS patients with CD95 DD mutations reported that the risk of non-Hodgkin and Hodgkin lymphomas, respectively, was 14 and 51 times greater than expected [177]. Collectively, all diseases associated with abnormal lymphocyte apoptosis, lymphoproliferation, and autoimmunity, are named Autoimmune Proliferative Syndromes. The syndromes can be classified according to the mutated gene(s) responsible for the defect and they are usually characterized by lymphadenomegaly and hepatosplenomegaly associated with autoimmune manifestations, mainly of the hematological type, such as hemolytic anemia, thrombocytopenia, and neutropenia, as well as the presence of cell-type-specific autoantibodies [178–180]. Furthermore, the accumulation of a minority population of self-reactive CD3<sup>pos</sup> TCR<sup>pos</sup> CD4<sup>neg</sup> CD8<sup>neg</sup> T cells called double negative (DNT) has been reported in the early 1990s as a major feature of ALPS. Despite their similarity to normal differentiated T cells, DNTs are remarkably proliferative, particularly in the paracortical region [181]. Last year Kimberly Gilmour’s group carried out a study on 215 patients with clinical evidence of ALPS, intending to define the most useful and predictable biomarkers for a better ALPS diagnosis. Among the several subgroups of patients, levels of different biomarkers, including DNTs and sCD95L, were observed significantly higher in the ALPS-FAS patients than in the “unknown ALPS” (ALPS-U), cases for which the genetic determinant is not identified. They developed a diagnostic protocol for the potential identification of patients with presymptomatic or mild disease. The combination of such biomarkers could be useful in the process of confirming or excluding the ALPS diagnosis [182]. Today the diagnosis requires performing a cell apoptosis test and molecular type analysis, and the choice of therapy is guided by the severity and nature of the symptoms, but generally it is based on the intake of immunosuppressants such as rituximab. The increased sCD95L serum levels are now part of the new diagnostic criteria procedure for an ALPS [183, 184]; these high levels have indeed been associated with the pathology without their pathophysiological role being elucidated [185]. Curiously, some groups observed a change in sCD95L levels in correlation with aging, and age-related conditions and/or diseases with an increase in molecular signals due to aging oxidative stress [186]. Furthermore, oxidative stress seems to promote CD95L cleavage through activation of MMPs, and more interestingly this MMP activation seems to increase as a function of aging [187].

**SLE: Systemic lupus erythematosus.** In both humans and mice, mutations in the genes coding for CD95 or CD95L are also strongly associated with certain forms of lupus disease. The defects in apoptosis described in autoimmunity and lymphoproliferative syndromes correspond to the human equivalent of the MRL/lpr mouse model (Murphy Roths Large/lymphoproliferation), deeply investigated as a murine SLE-like model [188, 189]. This model was generated following the identification of an autosomal recessive modification on chromosome 19 [190]. The mentioned mutation was found on the gene encoding CD95 protein. Similar to this model, a second model was designed and generated after the discovery of a second autosomal recessive mutation, on chromosome 1, corresponding to the gene coding for CD95L [191]. The latter model took the name of MRL/gld for generalized lymphoproliferative disease. In addition to these two mouse models, a wider selection of mouse models is available to sift genetic and cellular aspects of SLE [192, 193]. Since the etiology of SLE is multifactorial and multigenetic, some of these models, such as those mentioned above, derive from spontaneous genetic factors, while others assume a SLE-like phenotype after exposure to certain chemicals such as intraperitoneal injections of pristane (2, 6, 10, 14 tetramethylpentadecane) [194], or overexpression of cytokines (ie IL-6, IL-12, INF-1) [195–197]. Others, similarly to induced graft-versus-host disease models, develop a lupus-like syndrome following donor cell injection [198]. Despite their numerous limitations, over the years these SLE-like mouse models have been widely used to screen numerous potential therapies, pointing out their importance in the study of this disease and in the therapeutic advancement in this field [199]. Systemic lupus erythematosus is a rare systemic autoimmune disease, more severe in women, especially of childbearing age. Very recently Lars Rönnblom’s group has observed that there is a correlation between the cumulative genetic risk and survival, organ damage, renal dysfunctions, in patients affected by SLE, introducing Genetic Risks Score (GRS) as a potential tool for predicting outcomes in patients with SLE [200]. The term “systemic” means that the disease affects several organs. Genetically speaking, germline heterozygous mutations in the FAS gene have been
observed in pediatric cases with ALPS-FAS. These children develop symptoms similar to those of systemic lupus erythematosus disease [201]. According to Neven’s report, FAS mutations were located within the intracellular domain of CD95. On the other hand, germline mutations in the FASLG gene seem to be involved only in a minority of patients with SLE. This does not exclude the possible role of somatic mutations in the FASLG gene in some of the self-reactive clones that contribute to the expression of the disease [202]. High levels of sCD95L have also been detected in the serum of SLE patients, compared to those present in the serum of healthy donors [142]. This observation seems to suggest that high levels of sCD95L may be related to the aggravation of the disease, which constitute a new opening for the study of new therapeutic strategies. Indeed, to date, there are unfortunately no targeted therapies against SLE disease. The diagnosis of this heterogeneous disease is not always simple, as in the early stages the symptoms can simulate other pathologies. For instance, the first “red flags” are given by skin and joint symptoms, both of which can be traced back to multiple pathologies. Less commonly, various infections, as well as pathological conditions such as mixed connective tissue disease (MCTD) or sarcoidosis, can mimic the symptoms of lupus. As a general rule, the first test to be performed is the fluorescence analysis for the detection of antinuclear antibodies (ANA), commonly called autoantibodies. Indeed, 98% of patients with systemic lupus have a positive immunofluorescent ANA test. Several blood and kidney involvement tests are later performed to support the latter. Patients with SLE frequently develop haematopathological and nephropathological conditions, such as leucopenia, thrombocytopenia, haemolytic anaemia and active nephritis [203, 204]. The treatment of lupus is standardized and involves corticosteroids, immunosuppressants, and non-steroidal anti-inflammatory drugs in addition to hydroxychloroquine for mild disease [205, 206]. As for new therapeutic options, a large number of drugs, mainly monoclonal antibodies (mAbs), have been evaluated and tested with rather disappointing results. The main objective is to reduce the doses of corticosteroids and immunosuppressants used, as a chronic administration of these drugs causes complications such as infections or secondary osteoporosis [207, 208]. To date, Belimumab (anti-B-cell activating factor) is the only biotherapeutic approved for the treatment of the non-renal form of SLE [209]. The use of Belimumab as an addition to standard therapies seems to improve the quality of life of patients suffering from this disease, but the goal to replace “conventional” drugs remains to be demonstrated. The study conducted on the use of other monoclonal antibodies, for instance Rituximab (anti-CD20) and Anifrolumab (anti-type I interferon receptor), for the treatment of this pathological condition is still ongoing.

Organ-specific autoimmune. In contrast to systemic autoimmune diseases, organ-specific autoimmunity is characterized by a cell-mediated attack against a specific type of cell in a given target organ, thus causing tissue damage. Some examples of such clinical conditions are insulin-dependent diabetes mellitus, ulcerative colitis (UC), multiple sclerosis (MS), or Sjögren’s syndrome (SS), all conditions to which excessive CD95-mediated apoptosis can contribute [210, 211]. As previously stated, the CD95/CD95L complex plays a central role in controlling immune reactions via AICD. This process is crucial in regulating the autoantigen-dependent primary T-cell response. Therefore, CD95L-mediated AICD dysregulation could be implicated in the acceleration process of organ-specific autoimmune lesions. Furthermore, sCD95L secretion is generally increased in effector cells upon specific activation with organ-specific autoantigen [212]. sCD95L could thus act as an inhibitor of CD95-mediated AICD in these contexts, promoting effector T-cell proliferation and tissue lesions, as demonstrated for autoantigen-reactive CD4 T cells in SS mouse models [212]. Over the years, the numerous studies carried out on the role of the soluble form of CD95L in the context of organ-specific autoimmune diseases, have led to conflicting results. It seems that the role of soluble CD95L varies according to the type of disorder and the mouse model used. In 2019 a group showed on non-obese diabetes mice (NOD) lacking sCD95L and maintaining mCD95L and immune homeostasis that sCD95L does not markedly affect islet inflammation, hence the pathogenesis of autoimmune diabetes, but more interestingly that sCD95L deficiency does not alter immune homeostasis in NOD mice [213].

CURRENTLY USED CANCER THERAPIES

Since the discovery of CD95 [214–217], it has been thought possible to exploit the physiological importance of CD95/CD95L to develop new powerful chemotherapeutic agents. However, it was quite soon discovered that systemic administration of CD95 agonists resulted in severe toxicity [218]. It was observed that these agents induced massive apoptosis of hepatocytes resulting in a form of fulminant hepatitis, lethal to the treated animals [219, 220]. Over the past two decades, controversies over the different implications assumed by the CD95/CD95L system in various diseases such as cancer, autoimmune diseases and inflammatory diseases have made it difficult to identify targeted therapies. Several studies have developed interesting approaches to strengthen the apoptotic function of CD95 and limit the side effects deriving from the non-specificity of the previously developed molecules. Some of these studies will be described in this review. Unfortunately, very few of these approaches have reached clinical trials (Table 1: Breakdown of the patents targeting Death Receptors and/or their ligand).

It is now well established that the apoptotic signal is often defective in cancer and that the CD95/CD95L interaction is involved in the tumor cells’ escape from the immune surveillance system. For instance, some tumor cell types [221], i.e., some cancer cells, effector T cells (CD8<sup>pos</sup>), regulatory T cells (CD4<sup>pos</sup>, CD25<sup>pos</sup>), tumor endothelial cells, Myeloid-derived suppressor cells (MDSC), Monocyte-derived human macrophages (MDM), Cancer-associated fibroblasts (CAF), Cancer stem cells (CSC), are able to express CD95L at the membrane, thus conferring the tumor environment a “counterattack” mechanism involved in the elimination of tumor-infiltrating lymphocytes and prevention of successful immunotherapy [222–228]. Interestingly, it was observed that the vascular endothelial cells of some solid tumors also express the membrane-bound form of CD95L through a mechanism involving tumor-derived vascular endothelial growth factor A (VEGF-A), interleukin 10 (IL-10) and prostaglandin E2 (PGE2) [229]. CD95L expression becomes here a defense barrier against CD8<sup>pos</sup> T cells, preventing their extravasation and their access to the tumor nest [230]. Furthermore, it has been observed that different types of cancer cells release vesicles called Tumor- Derived Exosome (TEX) into the microenvironment, which act as messengers between cells. TEX can carry several immunosuppressive molecules, including membrane-bound CD95L. This represents a further defense mechanism by the tumor cells against the CD8<sup>pos</sup> T cells that manage to infiltrate the tumor nest [231]. TEX can inhibit the proliferation of CD8<sup>pos</sup> T cells by apoptotic induction, thus playing a major role in immune evasion [232, 233]. In this context, engineered exosomes appears interesting to design potential immunotherapies such as cancer vaccines [234]. Moreover, inhibition of CD95L could prevent cancer resistance to radiotherapeutic or immunotherapeutic treatments, thus representing another path to follow in cancer immunotherapy. Today it is possible to predict, assess and monitor whether a subject with cancer is sensitive to treatment with immunotherapeutics. The Gustave Roussy institute has published a method and kits to determine if in a sample of a said subject one or more biomarkers, including CD95<sup>pos</sup> CD4<sup>pos</sup> T cells, CD95<sup>pos</sup> CD8<sup>pos</sup> T cells is present/
| N° | Publication Id | Publication date | Country | Disease | Approach | Title | Inventors |
|----|----------------|------------------|---------|---------|----------|-------|-----------|
| 1  | WO2003079750  | 2003.10.02       | WO      | Autoimmune diseases/inflammatory diseases/cancer | Antibodies | Antagonistic anti-hfas ligand human antibodies and fragments thereof | LANCASTER Joanne Sloan |
| 2  | US20200102397/ WO2017051002 | 2020.04.02/2017.03.30 | WO | Cancer | Antibodies | Anti-CD95 antibody | GIEFFERS Christian, THIELER Oliver, THIEMANN Meinolf et al. |
| 3  | WO2015165973  | 2017.03.08       | WO      | Cancer | Antibodies | Diagnostic anti-CD95 antibody | FRICKE, Harald GIEFFERS, Christian SYKORA, Jaromir |
| 4  | WO2008080623  | 2016.04.28       | WO      | Cancer | Antibodies | Neutralization of CD95 activity blocks invasion of glioblastoma cells in vivo | MARTIN-VILLALBA Ana, KLEBER Susanne, WIESTLER Benedikt et al. |
| 5  | US20150274833/ EP2014076292 | 2015.10.01/2014.05.22 | WO | Cancer | Antibodies | Recombinant bispecific antibody binding to CD20 and CD95 | HERRMANN Andreas, GROSSE-HOEST ludger |
| 6  | EP2179111/ WO2012168259 | 2014.04.16/2012.12.13 | WO | Cancer | Antibodies | Protein tyrosine phosphatase, non-receptor type 11 (PTPN11) and triple-negative breast cancer | BENTIRES-ALJ Mohamed, ACETO Nicola, STADLER Michael |
| 7  | US20060083738/ EP2003097698 | 2006.04.20/2003.11.27 | WO | Cancer | Antibodies | Treatment of cancer by the use of anti-CD95 antibody | JOHNSTON Patrick Gerard, Llongley Daniel |
| 8  | WO2010066914  | 2011.10.19       | WO      | Others | Antibodies | Remedies for pemphigus containing anti-CD95 antibodies | PINCELLI Carlo, MARCONI Alessandra |
| 9  | US20030082180/ WO2010041803 | 2003.05.01/2001.06.14 | WO | Others | Antibodies | Combination of compounds that inhibit the biological effects of TNF-α and CD95 in a medicament | KRAMMER Peter, MARTIN-VILLALBA Ana |
| 10 | US20110300113/ EP2064235/ WO2008054608 | 2011.12.08/2009.06.03/2008.03.27 | WO | Others | Antibodies/cells | The death receptor CD95 controls neurogenesis of adult neural stem cells in vivo and in vitro | MARTIN-VILLALBA Ana, CORSINI Nina, LETELLIER Elisabeth et al. |
| 11 | WO2010006722  | 2011.08.04       | WO      | Inflammatory diseases | Antibodies/fusion proteins | Use of CD95 inhibitors for the treatment of inflammatory disorders | MARTIN-VILLALBA Ana, LETELLIER Elisabeth, SANCHEZ MARTINEZ Ignacio |
| 12 | US20170166648/ EP3160224/ WO2014013036 | 2017.06.15/2017.04.05/2014.01.23 | WO | Others | Antibodies/fusion proteins | Inhibitors of the CD95 signaling pathway for treatment of md | FRICKE Harald, FONTENAY Michaela, KUNZ Claudia |
| 13 | US20060234968/ WO2004071528 | 2006.10.19/2004.08.26 | WO | Others | Antibodies/fusion proteins | Inhibition of the CD95 ligand/receptor system for the treatment of neurological disorders and injuries | MARTIN-VILLALBA Ana, KRAMMER Peter, DEMUEN Deana |
| 14 | US20030170244 | 2003.09.11 | US | Cancer/others | Antibodies/fusion proteins | Inhibition of fas signaling | PLUINNKE John D, CONNOR Timothy |
| 15 | US6466637/ WO1999065935 | 2005.01.25/1999.12.23 | WO | Cancer/autoimmune diseases/others | Antibodies/polypeptides | Fas peptides and antibodies for modulating apoptosis | CHIODI Francesca |
Table 1.  

| N°  | Publication Id | Publication date | Country | Disease | Approach                                      | Title                                                                                     | Inventors                              | Ref. |
|-----|----------------|------------------|---------|---------|-----------------------------------------------|-------------------------------------------------------------------------------------------|----------------------------------------|------|
| 16  | WO2016170027   | 2016.10.27       | WO      | Inflammatory diseases | Antibodies/polypeptides  | Methods and pharmaceutical compositions for the treatment of th17 mediated diseases   | LEGEMBRE Patrick, BLANCO Patrick, FLYNN Robin | [101]|
| 17  | US20120294856/EP2502069/WO2011058175 | 2012.11.22/2012.09.26/2011.05.19 | WO      | Cancer | Antigens/antibodies/enzymes/RNA interfering molecules | Compounds inhibiting cd95 signaling for the treatment of pancreatic cancer | MARTIN-VLALBA Ana, HERHAUS Peter, SANCHEZ-MARTINEZ Ignacio et al. | [363]|
| 18  | US20020407728/WO2016069282 | 2020.12.31/2016.05.06 | WO      | Autoimmune diseases | Cells | Altering gene expression in modified t cells and uses thereof | ZHAO Yangbing, REN Jiatao, LIU Xiaojun, JUNE Carl H. | [364]|
| 19  | US20150104428/EP2833896/WO2013149211 | 2015.04.16/2015.02.11/2013.10.03 | WO      | Autoimmune diseases | Cells | Compositions and treatment methods for mesenchymal stem cell-induced immunoregulation | SHI Songtao, AKIYAMA Kentaro, CHEN Chider | [330, 331]|
| 20  | WO2015038665 | 2015.03.19       | WO      | Autoimmune diseases/inflammatory diseases | Cells | A composition of stem cells having highly expressed fas ligand | SHI Songtao, LIU Shiyu, CHEN Fa-ming | [365]|
| 21  | US20200121719/EP3565888/WO2018129332 | 2020.04.23/2019.11.13/2018.07.12 | WO      | Cancer | Cells | Expansion of tumor-infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists | LOTZE Michael, T, RIITHIPICHAI Krit | [277, 366, 367]|
| 22  | EP3569700/WO2011052545 | 2019.11.20/2011.05.05 | WO      | Cancer | Cells | Method for producing antigen-specific b-cell population | KITAMURA Daisuke, NOJIMA Takuya | [368]|
| 23  | US20180008670 | 2018.01.11       | US      | Cancer | Cells | Chimeric antigen receptor targeting of tumor endothelium | WHITE David J | [370]|
| 24  | WO2015161276 | 2015.10.22       | WO      | Cancer | Cells | Crispr-cas-related methods, compositions and components for cancer immunotherapy | WELSTEAD G. Grant, FRIEDLAND Ari E, MAEDER Morgan L, BUMCROT David A | [369]|
| 25  | WO2014039044 | 2014.13.03       | US      | Cancer | Cells | Methods of producing t memory stem-cell populations | GATTINONI Luca, LUGI Enrico, ROERER Mario, RESTIFO Nicholas P | [281, 370, 371]|
| 26  | US20040131599/WO2002072798 | 2004.07.08/2002.09.19 | WO      | Cancer | Cells | Expansion of tumor-infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists | LOTZE Michael, T, RIITHIPICHAI Krit | [277, 366, 367]|
| 27  | US20090191167/EP2046351/WO2008014470 | 2009.07.30/2009.04.15/2008.01.31 | WO      | Cancer/autoimmune diseases/other | Cells | Adult sertoli cells and uses thereof | WHITE David J | [373]|
| 28  | WO2018227286 | 2018.12.20       | WO      | Inflammatory diseases/other | Cells | Allograft tolerance without the need for systemic immune suppression | NAGY Andras, HARDING Jeffrey, NAGY Kristina | [374]|
| 29  | WO2018130679 | 2019.11.20       | WO      | Cancer | Chemicals | Methods and pharmaceutical compositions for reducing cd95- mediated cell motility | LEGEMBRE Patrick, VACHER Pierre, POISSONNIER Amanda, BLANCO Patrick | [101]|

References:
| N° | Publication Id          | Publication date | Country | Disease              | Approach                | Title                                                                 | Inventors                                      | Ref. |
|----|-------------------------|------------------|---------|----------------------|-------------------------|-----------------------------------------------------------------------|------------------------------------------------|------|
| 30 | US20190084987           | 2019.03.21       | US      | Cancer               | Chemicals               | Small molecule histone methyltransferase suv39h1 inhibitor and uses thereof | LU Chunwan, LEBEDEVA Iryna, LIU Kebin          | [301]|
| 31 | US20150343024/EP2931375/WO2014090224 | 2015.12.03/2015.10.21/2014.06.19 | WO      | Cancer               | Chemicals               | Use of active substance combinations for inducing tumor senescence      | RÖCKEN Martin, WIEDER Thomas, HAHN Matthias et al. | [375]|
| 32 | WO2008036244           | 2008.03.27       | WO      | Cancer               | Chemicals               | Use of cyclosporin a to sensitize resistant cancer cells to death receptor ligands | REED John C, THOMAS Michael P                   | [376]|
| 33 | WO2019206834           | 2019.10.31       | WO      | Cancer/autoimmune diseases | Chemicals               | Compounds and pharmaceutical compositions for reducing cd95-mediated cell motility | VACHER Pierre, LEGEMBRE Patrick, JEAN Mickael et al. | [142]|
| 34 | WO2002047728           | 2002.06.20       | WO      | Others               | Chemicals               | Treatment of posterior capsule opacification                           | ALLAN Bruce, Duncan Samuel                     | [377]|
| 35 | WO2019141862           | 2019.07.25       | WO      | Inflammatory diseases | Chemicals/antibodies/fusion proteins/nucleotide complexes | Combination therapeutics                                              | WALCZAK Henning, TARABORRELLI Lucia, PBLTZER Nieves | [321]|
| 36 | US20090142369          | 2009.06.04       | US      | Others               | Cosmetic composition   | Method for preventing skin-cellular injury by using green algae extract and cosmetic composition containing green algae extract | SHIH Meng-Han, SHIH Mei-Fen                    | [378]|
| 37 | US20080118466          | 2008.05.22       | US      | Autoimmune diseases  | Drug delivery system   | Treatment of rheumatoid arthritis with soluble fas-ligand cross-linkers | HUREZ Vincent Jacques, MICHELSON Seth G, SHODA Lisi Katharine et al. | [379, 380]|
| 38 | EPO0930890/ WO1998017305 | 1999.07.28/1998.04.30 | WO      | Autoimmune diseases  | Drug delivery system   | Use of fas or fast transfected cd4+/-/fasl?-/th1-cell lines for the treatment of th1/th2 diseases | HAHNE Michael, TSCHOPP Juerg, DA CONCEICAO-O-Silva Fatima, SCHROETER Michael | [381]|
| 39 | US20200046780/EP3592392 | 2020.02.13/2020.01.15 | US/EP   | Autoimmune diseases/others | Drug delivery system   | Fas-engineered biomaterials with immunomodulatory function               | SHIRWAN Haval, GARCIA Andres J, YOLCU Esma S et al. | [136, 382]|
| 40 | US20050214311/EP1478390/WO2003070271 | 2005.09.29/2004.11.24/2003.08.28 | WO      | Cancer              | Drug delivery system   | Novel complexes for inducing an immune response                          | SCREATON Gavin R, SIMON Katharina A, GALLIMORE Awen M | [383]|
| 41 | US20200108117/WO2019246130 | 2020.04.09/2019.12.26 | US      | Cancer/others       | Drug delivery system   | Drug delivery systems comprising an intracocular pressure lowering agent, a neurotrophic agent, a c-type natriuretic peptide, a natriuretic peptide receptor-b, an apoptosis signaling fragment inhibitor or a fas-ligand inhibitor for treating glaucoma or ocular hypertension | SCHIFFMAN Rhett M, SCHIBBLER Lukas | [384]|
| 42 | US20200246432/WO2019040372 | 2020.08.06/2019.02.28 | WO      | Others              | Drug delivery system   | Nitric oxide- and fas ligand-eluting compositions and devices and methods of treatment using same | KURAL M Hamdi, GUI Lijiong, NIKLASON L Elizabeth, SALTZMAN William Mark | [385]|

Table 1. continued
| N° | Publication Id | Publication date | Country | Disease | Approach | Title | Inventors | Ref. |
|----|----------------|------------------|---------|---------|----------|-------|-----------|------|
| 43 | WO2019246141   | 2019.12.26       | WO      | Others  | Drug delivery system | Drug delivery systems comprising a neurotrophic agent, an apoptosis signaling fragment inhibitor (fas) or fas-ligand (fasl) inhibitor, a tumor necrosis factor-α (tnf-α) or tnf receptor inhibitor, a mitochondrial peptide, an oligonucleotide, a chemokine inhibitor, or a cysteine-asparatic protease | SCHIFFMAN Rhett M, SCHEIBLER Lukas | [384] |
| 44 | WO2019246130   | 2019.12.26       | WO      | Others  | Drug delivery system | Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension | SCHIFFMAN Rhett M, SCHEIBLER Lukas | [384] |
| 45 | US20040096450/ WO2000040263 | 2004.05.20/ 2000.07.13 | WO | Others | Drug delivery system | Methods and compositions for treating diseases associated with increased fas-ligand titers | FRENCH Lars E, VIARD Isabelle, TSCHOPP Jurg | [386] |
| 46 | US20190330305/ WO2014121085 | 2019.10.31/ 2014.08.14 | WO | Autoimmune diseases/ inflammatory diseases/cancer | Fusion proteins | Pd-l1 and pd-l2-based fusion proteins and uses thereof | TYIOCINSKI Mark L | [387] |
| 47 | EP1481687      | 2004.12.01       | EP      | Autoimmune diseases/ inflammatory diseases/cancer | Fusion proteins | Use of multimeric ligands of the tnf family with reduced toxicity for treating cell proliferative diseases | ROSAT Jean-Pierre | [294] |
| 48 | US20070269449/ WO2004085478 | 2007.11.22/ 2004.10.07 | WO | Autoimmune diseases/ inflammatory diseases/cancer | Fusion proteins | C95-fc fusion proteins | WALCZAK Henning | [388] |
| 49 | EP1214411/ WO2001018202 | 2002.06.19/ 2001.03.15 | WO | Autoimmune diseases/ inflammatory diseases/others | Fusion proteins | Flint analog compounds and formulations thereof | ATKINSON Paul Robert, TIAN Yu, WITCHER Derrick Ryan | [389–391] |
| 50 | WO2001090382   | 2001.11.29       | WO      | Autoimmune diseases/ inflammatory diseases/others | Fusion proteins | Fas ligand-fused proteins | TOUMA Jyunko | [392] |
| 51 | US20180318394/ EP3313429/ WO2016205714 | 2018.11.08/ 2018.05.02/ 2016.12.22 | WO | Autoimmune diseases/others | Fusion proteins | Immunomodulation for the long-term prevention and treatment of autoimmune diseases and foreign tissue rejection | SHIRWAN Haval | [382, 393, 394] |
| 52 | US20110081369/ EP1250055 | 2011.04.07/ 2002.10.23 | US/EP | Autoimmune diseases/others | Fusion proteins | Methods of immune modulation with death receptor-induced apoptosis | SHIRWAN Haval | [382, 393, 394] |
| 53 | US20110003385/ EP0804561 | 2011.01.06/ 1997.11.05 | US/EP | Autoimmune diseases/others | Fusion proteins | Regulated transcription of targeted genes and other biological events | CRABTREE Gerald R, SCHREIBER Stuart L, SPENCER David M | [395] |
| N° | Publication Id | Publication date | Country | Disease | Approach | Title | Inventors | Ref. |
|----|----------------|-----------------|---------|---------|----------|-------|-----------|------|
| 54 | US20090239240/EP2039768 | 2009.09.24/2009.03.25 | US | Autoimmune diseases/others | Fusion proteins | Mutant forms of fas ligand and uses thereof | KETING Chu [266] |
| 55 | US20180148512/WO2014121093 | 2018.05.31/2014.08.07 | WO | Cancer | Fusion proteins | Fusion proteins that facilitate cancer cell destruction | TYKOCINSKI Mark L [289] |
| 56 | WO2015197874 | 2017.05.03 | WO | Cancer | Fusion proteins | Combination of cd95/cd95i inhibition and cancer immunotherapy | KUNZ Claudia, FRICKE Harald, HÖGER Thomas, GAMER Juergen [266, 396–398] |
| 57 | US2015029774S/EP2897642/WO2014045022 | 2015.10.22/2015.07.29/2014.03.27 | WO | Cancer | Fusion proteins | Agents and methods | COBBOLD Mark, MILLAR David [399] |
| 58 | WO2012170072 | 2014.04.17 | WO | Cancer | Fusion proteins | Engineered antibody-tnfsf member ligand fusion molecules | GREWAL Iqbal, KHARE Sanjay D, GRESSER Michael, SYED Rashid |
| 59 | US20120177575/EP2456648/WO2011010156 | 2012.07.12/2012.05.30/2011.01.27 | WO | Cancer | Fusion proteins | Fas (apo-1,cd95) targeted platforms for intracellular drug delivery | ATEH Davidson D, MARTIN Joanne E [400] |
| 60 | US20110008842 | 2011.01.13 | US | Cancer | Fusion proteins | Chimeric nucleic acids encoding polypeptides comprising cd70 and fas-ligand domains | PRUSSAK Charles E, KIPPS Thomas J, CANTWELL Mark J [401] |
| 61 | EP3406630/US20180186856/WO2014013037 | 2018.11.28/2018.02.22/2014.01.23 | WO | Cancer/autoimmune diseases/inflammatory diseases/others | Fusion proteins | Nucleic acids encoding artificial signal peptides and methods of production thereof | HILL Oliver, GIEFFERS Christian, THIEMANN Meinolf [324, 325, 346, 348, 402] |
| 62 | WO2014013039 | 2014.01.23 | WO | Cancer/autoimmune diseases/inflammatory diseases/others | Fusion proteins | Composition comprising a mixture of cd95-fc isoforms | HILL Oliver, GIEFFERS Christian, THIEMANN Meinolf [324, 325, 402] |
| 63 | WO2013060864 | 2014.09.03 | WO | Cancer/autoimmune diseases/others | Fusion proteins | Chimeric molecule involving oligomerized fas extracellular domain | TAUPIN Jean-Luc, DABURON Sophie, MOREAU Jean-François, CAPONE Myriam [292, 293] |
| 64 | WO2008025516 | 2011.02.03 | WO | Cancer/inflammatory diseases/others | Fusion proteins | Cd95l or trail fusion proteins | HILL Oliver, GIEFFERS Christian, THIEMANN Meinolf [324, 325, 402] |
| 65 | US20190016782/WO2014106839 | 2019.01.17/2014.07.10 | WO | Cancer/others | Fusion proteins | Stable form of signal converting protein fusion proteins, and methods of use and preparation thereof | DRANITZKI ELHALE Li, Michal, SHANI Noam [266] |
| 66 | EP2042509/US20070154905/WO1997003998 | 2009.04.01/2007.07.05/1997.02.06 | WO | Cancer/others | Fusion proteins | Modulators of the function of fas receptors and other proteins | WALLACH David, BOLDIN Mark, GONCHAROV Tanya, GOLSTEY Yuri V [403] |
| 67 | WO2007022273 | 2007.02.22 | WO | Cancer/others | Fusion proteins | Vegf-activated fas ligands | QUINN Timothy P [404, 405] |
| 68 | US20040147447/WO1999066039 | 2004.07.29/1999.12.23 | WO | Cancer/others | Fusion proteins | Tnfr-like protein with death domain | LU Jian J, GOMES Bruce C, FIELDS William E |
| \#  | Publication Id | Publication date | Country | Disease | Approach | Title | Inventors | Ref. |
|----|----------------|------------------|---------|---------|----------|-------|-----------|------|
| 69 | US20110171212 | 2011.07.14       | US      | Inflammation diseases | Fusion proteins | Methods and compositions for preventing radiation-induced pneumonitis | BELKA Claus, HERBST Jörg | [406] |
| 70 | US20040176279/WO2002060949 | 2002.08.08 | WO | Inflammatory diseases/others | Fusion proteins | Glycoforms a fas-ligand inhibitory protein analog | JENKINS Nigel, WITCHER Derrick R, WROBLEWSKI Victor J | [407] |
| 71 | US20160340409/EP2621514/WO2012042480 | 2016.11.24/2013.08.07/2012.04.05 | WO | Others | Fusion proteins | Compositions and methods for treatment of hematological malignancies | DRANITZKI ELHALEL Michal | [266] |
| 72 | US20040018170 | 2004.01.29 | US | Others | Fusion proteins | Fas ligand-avidin/streptavidin fusion proteins | SHIRWAN Haval | [382, 393, 394] |
| 73 | EP1097226/WO2000003023 | 2001.05.09/2000.01.20 | WO | Cancer/autoimmune diseases/others | Fusion proteins | Usurpin, a mammalian ded-caspase homologue that precludes caspase-8 recruitment and activation by the cd95 (fas, apo-1) receptor complex | NICHOLSON Donald, W, RASPER Dita M, XANTHOUDAKIS Steve, ROY Sophie | [408] |
| 74 | EP3337509/US20170051352 | 2018.06.27/2017.02.23 | US/EP | Autoimmune diseases | Method | Methods of treating autoimmune conditions in patients with genetic variations in dcr3 or in a dcr3 network gene | HAKONARSON Hakon, KAO Charly, CARDINALE Christopher et al. | [409] |
| 75 | US20160194714 | 2016.07.07 | US | Autoimmune diseases | Method | Biomarkers for predicting relapse in multiple sclerosis | RUS Horea, TEGLA Cosmin | [306–309] |
| 76 | US20160208332 | 2016.04.07 | US | Autoimmune diseases | Method | Diagnosis and prognosis of multiple sclerosis | RUS Horea, CUDRICI Cornelia, TEGLA Cosmin | [306–309] |
| 77 | US20100285600/EP1891233/WO2006116602 | 2010.11.11/2008.02.27/2006.11.02 | WO | Autoimmune diseases | Method | Markers associated with the therapeutic efficacy of glatiramer acetate | LANCET Doron, BECKMANN Jacques, AVIDAN Nili et al. | [410] |
| 78 | US20090074670/WO2002002751 | 2009.03.19/2002.01.10 | WO | Autoimmune diseases/others | Method | Alteration of cell membrane with fasl | SHIRWAN Haval | [411] |
| 79 | WO2015107105 | 2016.11.23 | WO | Cancer | Method | Method of predicting the responsiveness of a cancer disease to treatment on the basis of dna methylation | FRICKE Harald | [297–299] |
| 80 | WO2015104284 | 2016.11.16 | WO | Cancer | Method | Methods and pharmaceutical compositions for preventing or reducing metastatic dissemination | LEGEMBRE Patrick, SEGUL Bruno, LEVADE Thierry, MICHEAU Olivier | [296, 412] |
| 81 | WO2014118317 | 2015.12.31 | WO | Cancer | Method | Methods for predicting and preventing metastasis in triple-negative breast cancers | LEGEMBRE Patrick, MALLET Marine, TAUZIN Sébastien et al. | [141] |
| 82 | US20150098924/WO2006037762 | 2015.04.09/2006.04.13 | WO | Cancer | Method | Method for ex-vivo purging in autologous transplantation | DUPUIS Marc, GREANEY Peter, DUCHOSAL Michel | [413] |
| 83 | EP1668360/US20050069963 | 2006.06.14/2005.03.31 | US/EP | Cancer | Method | Multifactorial assay for cancer detection | LOKSHIN Anna E, GORELIK Elieser | [414] |
| 84 | US20050158807/WO2003056340 | 2005.07.21/2003.07.10 | WO | Cancer | Method | Fadd proteins, phosphorylated p38-mapk and fasl as tumor markers | CHIOCCHIA Gilles, TOURNEUR Lea, FEUNTEUN Jean et al. | [415] |
| 85 | WO2005053739 | 2005.06.16 | WO | Cancer | Method | Combination therapy | JOHNSTON Patrick G, LONGLEY Daniel | [416] |
| №     | Publication Id | Publication date | Country | Disease                  | Approach                                                                 | Title                                                                                           | Inventors                                      | Ref. |
|-------|----------------|------------------|---------|--------------------------|--------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|-----------------------------------------------|------|
| 86    | EP1127075/ WO20000027883 | 2001.08.29/2000.05.18 | WO      | Cancer                   | Method                                                                   | A method of treating tumors using fas-induced apoptosis                                    | DONG Jian-Yun, NORRIS James S                  | [417]|
| 87    | WO2001048238  | 2001.07.05        | WO      | Cancer                   | Method                                                                   | Chemotherapeutant screening method                                                          | KRAMMER Peter, EICHORST Sören, LI-WEBER Min, MÜLLER-SCHILLING Martina | [418]|
| 88    | WO1999003998  | 1999.01.28        | WO      | Cancer                   | Method                                                                   | Methods and compositions for tumor reduction                                                 | NABEL Gary J                                  | [419]|
| 89    | US6153385/ WO1997020067 | 2000.11.28/1997.06.05 | WO      | Cancer/ autoimmune diseases/others | Method                                                                   | Process for detecting the expression of cd95 ligand in cells                               | DEBATIN Klaus-Michael, HERR Ingrid             | [420]|
| 90    | EP0876503/ WO1997020064 | 1996.11.11/1997.06.05 | WO      | Cancer/ autoimmune diseases/others | Method                                                                   | Process for assessing the activity of drugs                                                  | DEBATIN Klaus-Michael, FRIESEN Claudia, KRAMMER Peter, HERR Ingrid | [420]|
| 91    | EP0689600/ WO1994020625 | 1996.01.03/1994.09.15 | WO      | Cancer/others             | Method                                                                   | Process to induce the death of tumor cells                                                   | WONG Grace H W                                | [421]|
| 92    | WO1999003999  | 1999.01.28        | WO      | Inflammatory diseases     | Method                                                                   | Methods and compositions for inhibiting the pro-inflammatory response                       | NABEL Gary J, CHEN Jian-Jun                    | [422]|
| 93    | US20020127233 | 2002.09.12        | US      | Inflammatory diseases/cancer/others | Method                                                                   | Method for inhibiting inflammation in immune privileged sites using fas-ligand fragments  | ZHU Bing, CYNADER Max S, PATY Donald W, LUO Ling | [423]|
| 94    | US20180369380  | 2018.12.27        | US      | Others                   | Method                                                                   | Methods and compositions for treating conditions of the eye                                | GRAGOU DAS Evangelos S, POULAKI Vasiliki, MILLER Joan W | [424]|
| 95    | US2014045198/ EP2678688/ WO2012113760 | 2014.02.13/2014.01.01/2012.08.30 | WO      | Others                   | Method                                                                   | Method of predicting the evolution of a patient suffering of a neurovascular disease        | MONTANER VILALONGA Joan, ROSELL NOVEL Anna, NAVARRO SOBRINO Miriam | [357, 425]|
| 96    | US20110294690/ EP2338058/ WO2010031821 | 2011.12.01/2011.06.29/2010.03.25 | WO      | Others                   | Method                                                                   | Differential diagnostic biomarkers of stroke mimicking conditions and methods of use thereof | MONTANER VILALONGA Joan                         | [357, 425]|
| 97    | US20060241150/ WO20050000405 | 2006.10.26/2005.01.06 | WO      | Others                   | Method                                                                   | P38 kinase inhibitor compositions and methods of use                                       | WEINER David B, MUTHUMANI Karuppiah            | [426]|
| 98    | WO20060777232  | 2006.07.27        | WO      | Others                   | Method                                                                   | Multimeric soluble fas-ligand for eliminating alloreactive t lymphocyte in allogenic hematopoietic stem-cell transplantation transplantation | DUPUIS Marc, DEMOTZ Stéphane, GREANEY Peter et al. | [413, 427]|
| 99    | US20050129684  | 2005.06.16        | US      | Others                   | Method                                                                   | Methods for preserving the viability of photoreceptor cells by anti-fas-ligand/anti-fas-receptor antibodies | ZACKS David, MILLER Joan W                     | [428]|
| 100   | US20030224403  | 2003.12.04        | US      | Others                   | Method                                                                   | Lethal toxin cytopathogenicity and novel approaches to anthrax treatment                   | POPOV Serguei G, CARBON Edith G, CARDWELL Jennifer | [429]|
| N° | Publication Id | Publication date | Country | Disease | Approach | Title | Inventors | Ref. |
|----|----------------|------------------|---------|---------|----------|-------|-----------|------|
| 101| US6524821/ WO2000007618 | 2003.02.25/ 2000.02.17 | WO | Others | Method | Anti-apoptotic compositions comprising the r1 subunit of herpes simplex virus ribonucleotide reductase or its n-terminal portion; and uses thereof | LANGELIER Yves, MASSIE Bernard | [430] |
| 102| US6485929/ WO1999036091 | 2002.11.26/ 2000.07.22 | WO | Others | Method | Method for inhibiting cd95-independent apoptosis in aids | KRAMME, Peter H, BERNDT Christina | [431] |
| 103| WO2015189236 | 2015.12.17 | WO | Cancer | Method | Methods and pharmaceutical compositions for reducing cd95-mediated cell motility | LEGEMBRE Patrick, COUNILLON Laurent, LAGADIC-GOSSMANN Dominique | [295] |
| 104| US2003011865/ WO2000059538 | 2002.06.06/ 2000.10.12 | WO | Autoimmune diseases/others | Nucleotide complexe | Antigen-specific induction of peripheral immune tolerance | AUGUST Thomas J, LEONG Kam W, GEORGANTAS Robert | [432] |
| 105| WO2001051503 | 2001.07.19 | WO | Cancer | Nucleotide complexe | Polynucleotides for inhibiting metastasis and tumor cell growth | BARBERA-GUILLEM Emilio | [433] |
| 106| US200200242064/ EP1121438/ WO2000022383 | 2002.04.11/ 2001.08.08/ 2000.04.27 | WO | Cancer/ autoimmune diseases/others | Nucleotide complexe | PS3 binding areas | KRAMMER Peter, MÜLLER-SCHILLING Martina, OREN Moshe | [251] |
| 107| US20040033979/ EP1176966 | 2004.02.19/ 2002.02.06 | US/EP | Cancer/ autoimmune diseases/ inflammatory diseases | Nucleotide complexe | Antisense modulation of fas mediated signaling | DEAN Nicholas M, MARCUSON Eric G, WYATT Jacqueline, ZHANG Hong | [434] |
| 108| US20030119776/ EP313853 | 2003.06.26/ 2003.05.28 | US/EP | Cancer/ autoimmune diseases/other | Nucleotide complexe | Modulation of fas and fas expression | PHILLIPS Nigel C, FILON Mario C | [435] |
| 109| US20070190607/ WO2001058953 | 2007.08.16/ 2001.08.16 | WO | Autoimmune diseases | Polypeptides | Inhibitors of pre-ligand assembly domain and function of the tumor necrosis factor receptor family | LENARDO Michael J, CHAN Francis Ka-Ming, SIEGEL Richard M | [36] |
| 110| US70977972/ WO1996625051 | 2006.08.29/ 1996.08.22 | WO | Autoimmune diseases/ inflammatory diseases/cancer | Polypeptides | Method and composition for regulating apoptosis | DIXIT, Vishwa M | [436] |
| 111| US20120245081 | 2012.09.27 | US | Autoimmune diseases/ inflammatory diseases/other | Polypeptides | Fas peptide mimetics and uses thereof | GREENE Mark I, MURALI Ramachandran, HASEGAWA Akihiko | [437] |
| 112| US20070184522/ EP1737483/ WO2000517940 | 2007.08.09/ 2007.01.03/ 2005.12.15 | WO | Autoimmune diseases/other | Polypeptides | Cell death modulation via antagonists of fasl and fas activation | ZARNEGAR Abdolreza, DEFRANCES Marie C, ZOU Chun-Bin | [438] |
| 113| US6451759/ WO1999036079 | 2002.09.17/ 1999.07.22 | WO | Autoimmune diseases/other | Polypeptides | Noncleavable fas ligand | KANG, Sang-Mo, BAAK, Dries BAEKESKOV, Steinnunn STOCK, Peter, G. | [439] |
| 114| WO2020132465 | 2020.06.25 | WO | Cancer | Polypeptides | Methods and compositions related to therapeutic peptides for cancer therapy | BECKER Lev, CUI Chang | [286] |
| N°  | Publication Id | Publication date | Country | Disease | Approach | Title | Inventors | Ref. |
|-----|----------------|------------------|---------|---------|----------|-------|-----------|------|
| 115 | EP2102234/ WO2008067305 | 2009.09.23/ 2008.05.06 | EP      | Cancer  | Polypeptides | Polypeptides comprising intracytoplasmic death domain and nkg2d ligand domain | WAGNER Thomas E, WEI Yanzhang | [440] |
| 116 | US201900083050/ WO2015158810 | 2019.03.21/ 2015.10.22 | WO      | Cancer/ autoimmune diseases/inflammatory diseases | Polypeptides | Polypeptides and uses thereof for reducing cd95-mediated cell motility | LEGEMBRE Patrick, VACHER Pierre, SANSEAU Doriane et al. | [146] |
| 117 | EP125908/ WO2001028582 | 2002.07.31/ 2001.04.26 | WO      | Cancer/ inflammatory diseases/others | Polypeptides | Therapeutic applications of flint polypeptides | BUMOL Thomas F, COHEN Fredric J | |
| 118 | US20100941596/ WO2001002633 | 2010.02.18/ 2007.01.04 | WO      | Inflammatory diseases | Polypeptides | Amelioration of inflammatory arthritis by targeting the pre-ligand assembly domain (plad) of tumor necrosis factor receptors | LENARDO Michael, DENG Guo-Min, CHAN Francis Ka-Ming, ZHENG Lixen | [441] |
| 119 | US20100941596/ WO2009027350 | 2017.08.31/ 2009.03.05 | WO      | Inflammatory diseases/others | Polypeptides | Use of sco-spondin peptides for inhibiting or preventing neuronal apoptosis mediated by cell death receptor ligands | MEINIE Annie, LALLOUE Fabrice, JAUBERTEAU Marie-Odile | [442] |
| 120 | US20130288979/ EP2982685 /WO2012066103 | 2017.11.14/ 2016.02.10/ 2012.05.24 | WO      | Others | Polypeptides | Inhibitors of apoptosis and uses thereof | BARRBE Stéphanie, NARGEOT Joëlle, LEBEU Bernard et al. | [443] |
| 121 | US20010018416 | 2001.08.30 | US      | Others | Polypeptides | Compositions and methods for treating hepatitis-c | SLESAREV Vladimir I, DIMITROV Todor | [444] |
| 122 | US20060089491 | 2004.06.07 | US      | Cancer | Polypeptides/nucleotide complexes | Fas-ligand derived polypeptides | NAGATA Shigekazu, SUDA Takashi, TAKAHASHI Tomohiro, NAKAMURA Norio | [445] |
| 123 | US20090169599 | 2009.07.02 | US      | Others | Reprogrammed virus | Scientifically modulated and reprogrammed treatment (smart) fas/fasl virus technology intended to neutralize t-helper cells infected with the human immunodeficiency virus | SCHIBBER Lane Bernard, SCHIBBER II Lane Bernard | |
| 124 | EP2355833/ US20100324116 | 2011.08.17/ 2010.12.23 | US/EP   | Cancer | RNA interfering molecules | Fas/fasl or other death receptor targeted methods and compositions for killing tumor cells | KRUSE Carol, TRITZ Richard | [283] |
| 125 | US20050119212 | 2004.06.18 | US      | Autoimmune diseases/others | RNA interfering molecules | Rna interference mediated inhibition of fas and fasl gene expression using short interfering nucleic acid (sina) | HAEBERLI Peter, MCSWIGGEN James | [446] |
| 126 | US20070004666 | 2007.01.04 | US      | Cancer/ autoimmune diseases/others | Transcription factors | Methods for modulating apoptotic cell death | LASHAM Annette, WATSON James D | [447, 448] |
| 127 | WO1998008965 | 1998.03.05 | WO      | Autoimmune diseases/others | Transcription factors/nucleotide complexes | Cd95 regulatory gene sequences and transcription factors | WATSON James D, RUDERT Fritz | [447, 448] |

The source of information used is the Patentscope of the WIPO IP Portal and the search was carried out by selecting only the patents published in the United States Patent Office and European Patent Office. Furthermore, the selection was made using keywords and selecting only the patents with these keywords in the title of the publication or the corresponding abstract on the front page. The keywords used are CD95, CD95L, CD95 ligand, Fas, Fast, Fas ligand.
absent together with its expression level (WO2017140826). In 2019, the soluble metalloprotease-cleaved CD95L, associated with a large number of immune infiltrate cells, has been identified as a possible biomarker for tumor immune infiltration (CD3^{+} T and CD8^{+} T cells) in advanced HGSO (High-Grade Serous Ovarian Cancer) [235]. These biomarkers can facilitate the identification of cancer patients prone to respond or resist to proposed immunotherapy and therefore to select an appropriate and personalized chemotherapy treatment. In the last 20 years, the strategies adopted in cancer immunotherapy can be classified into the two large families of active and passive immunotherapy.

**Active approaches**

Active immunotherapy is based on the principle that the drug stimulates the patient’s immune response against the tumor, thus acting indirectly. On the contrary, in the case of passive immunotherapy, the drug is directly capable of destroying the tumor cell. Among the active forms of immunotherapy recognized by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), should be mentioned the immunomodulatory mAbs, which mostly inhibit the immuno-suppressive receptors expressed by activated T cells (e.g., Ipilimumab inhibiting CTLA-4 and Pembrolizumab inhibiting PD-1), the immunostimulatory cytokines, generally used as adjuvants of other anticancer immunotherapies (e.g., IL-2/ Proleukin – Ipilimumab), the immunogenic cell death (ICD) inducers, which exert their antitumoral effect through cytostatic and cytotoxic mechanisms.

**Immunomodulatory mAbs.** In some pathological conditions, the so-called immune system checkpoints act directly as a “brake” in the immune response against cancer. The role of immunomodulatory monoclonal antibodies mAbs is precisely to lift these inhibitions by “removing the brake” of the immune system. To date, the most common and most widely used are the inhibitors of checkpoint Cytotoxic T Lymphocyte-Associated Antigen-4 (CTLA-4), Programmed Death 1 (PD-1) and PD-L1 [236]. There are six drugs targeting PD-1 or PDL-1 and only one targeting CTLA-4 currently approved for use in therapy of different types of cancer. Recently, the combination of two inhibitory checkpoints (i.e., Ipilimumab (anti-CTLA-4) and Nivolumab (anti-PD-1) has also joined the list of approved drugs, showing good therapeutic efficacy in several studies and thus paving the way for new clinical trials in different types of cancers [237]. However, other immune checkpoints are targeted in preliminary stages of clinical development [238]. In recent years, bispecific antibodies have also been developed with the aim of targeting multiple checkpoints simultaneously (e.g., CTLA-4 and PD-1), thus amplifying the signal [239]. However, this double-targeting has so far showed a higher toxicity as compared to its corresponding single therapies. Some of these double-targeting systems will be described in later sections of this review.

**Immunostimulatory cytokines.** With a counterbalancing action, immunostimulatory cytokines act instead as “stimulators” of the immune response. Cytokines can promote the activation, proliferation and survival of lymphocytes (T, B, NK) so as to obtain an antitumor response. Interleukins, interferons and chemokines belong to this large family. The protagonists in the field of immuno-oncology are certainly interleukin-2 (IL-2), the first cytokine FDA approved for therapeutic purposes, IL-12, -15, -21, and interferon alpha (IFN-α), for a long time used for the treatment of hematological neoplasms, for renal carcinoma and melanoma [240]. Having a short half-life, the efficacy of these drugs is limited following their systemic administration. They also induce severe adverse effects before reaching therapeutic doses [241–243]. Today the new engineered generation of these cytokines is making its way into the world of oncological immunotherapy, with improved half-life, antitumor efficacy and toxicity [244].

**Immunogenic cell death inducers.** One of the most widely used ICD agents is Doxorubicin (DOX), a drug discovered in the late 1960s that acts as a DNA intercalating agent and induces apoptosis. As above-mentioned, it has been observed by several groups that some tumor cell lines express CD95L on their surface [245–249] and more importantly, that DOX-induced apoptosis is mediated by the expression of CD95L with the consequent induction of cell death by binding to CD95 [250]. This observation introduced a new perspective on the use of the targeted CD95/CD95L system. In the following years, several other cytotoxic drugs showed the ability to up-regulate the expression of CD95L in cancer cells. In addition to doxorubicin, among the many, we mention Cisplatin, Etoposide, 5-Fluorouracil, Methotrexate, and Bleomycin [251–253]. A parallel mechanism by which these DNA-damaging chemotherapy agents lead to autocrine or paracrine apoptosis of the cell involves the activation of the p53 system, which once activated acts as a transcription factor that regulates the expression of pro-apoptotic genes such as PUMA and BAX [254, 255]. Several studies have been conducted on the implication of p53 in the regulation of dose-dependent heavy side effects, the first of which is cardiotoxicity [256, 257]. Other studies explored the combination of DOX with different drugs with the aim to reduce both acute and chronic DOX-induced cardiotoxicity without affecting its p53-mediated anticancer activity. These studies mention beta-blockers (e.g., Carvedilol), iron-chelating agents (e.g., Dextrazoxane, DEX), angiotensin-converting enzyme inhibitors -ACEI- (e.g., Zofenopril) or even Flavonoids (e.g Frederine), used in combination with DOX for the attenuation of cardiotoxicity [258–261]. Very recently, Todorova et al. carried out a study in which a new combination of DOX and Dantrolene is proposed. Dantrolene appears to mitigate the cardiotoxicity of DOX without affecting its antitumor action in a breast cancer model [262]. Also in 2020, a team from China has developed a new method of co-administration of the DOX, according to which by pre-treating the triple-negative breast cancer cells MDA-MB-231 with Quercetin, followed by the DOX, it is possible to hinder the multidrug resistance of this aggressive cell line [263]. Taken together, these observations are promising for future development from a clinical point of view.

**Cancer vaccines.** The concept of cancer vaccines was first introduced in the 1990s when Bacillus Calmette-Guerin was approved by the FDA for the treatment of early-stage bladder cancer. To date, only three cancer vaccines have been approved by the FDA, due to the poor results often obtained in phases III and IV of the trials [264]. The cancer vaccine approach does not aim to prevent the cancer onset but to activate the immune system against cancer cells. The patentWO2015197874, published by a German team in 2017, proposes a combination of inhibition of the CD95/CD95L complex and cancer immunotherapy, such as a cancer vaccine [265–268]. As previously mentioned, CD95L expression on the tumor endothelium promotes an immunosuppressive environment through preferential killing of tumor-reactive CD8^{+} T cells. Thus, the cancer vaccine would try to get the immune system to mount an attack against cancer cells by using a simultaneous inhibition of the CD95L/CD95 signaling system. More specifically, this cancer vaccine would contain cancer antigens in the form of a protein, a fragment thereof, or as RNA or DNA encoding that protein, to stimulate the immune system against this antigen.

**Passive approaches**

**Monoclonal antibodies.** Passive forms of immunotherapy include mAbs that specifically target the receptors on the surface of neoplastic cells expressing “tumor-associated antigens” (TAA), by
altering their functions. Some of these antibodies can be administered in combination with chemotherapeutic agents so that the antibodies deliver these agents specifically to cancer cells. An example of such a system is represented by the combination of anti-CD95 antibodies with a chemotherapeutic agent such as 5-Fluorouracil or Toremudex (WO2003097698) [269, 355]. The goal is to synergize the pro-apoptotic effect of anti-CD95 mAbs with cancer chemotherapeutic agents to kill cancer cells. A different combination approach consists in genetically fusing a full-length monoclonal antibody targeting the cancer cell, such as rituximab, with a more biological component represented by a TNF superfamiliy ligand, such as CD95L, in its full-length, or a fragment thereof, thus offering two approaches to kill cancer cells. The antibody-TNFsf ligand fusion molecules would combine the specificity of the antibodies to the target antigen with the potent death-inducing properties of the TNFsf member ligand, thus providing improved efficacy and safety. The two combined killing approaches are thus performed through ADCC-independent apoptosis (Ab-dependent cellular cytotoxicity), and the second through the recruitment of effector cells to kill tumor targets (WO2012170072) [270]. Another technique involves the use of bispecific antibodies, the method of which consists of linking an antibody that reacts with the tumor cell to a second antibody that reacts with a cytotoxic effector cell. This is the case of patent WO2014076292 published by Balopharm AG concerning a bispecific antibody with a first binding site for the CD95 receptor and a second binding site for the CD20 antigen [271, 272, 351]. This strategy aims to improve the treatment carried out with rituximab, an antibody able to target and kill CD20 expressing malignant and normal B cells unspecifically, thus showing significant side effects. This technique brings the effector cell into close opposition to the tumor cell, producing increased tumoricidal activity. Overall, the results of preclinical tests performed on antibody systems referring to CD95 have been encouraging, but to date, none of these CD95-related molecules are currently in clinical trials.

**ACT adoptive cell transfer.** Adoptive cell transfer is another very promising type of passive immunotherapy, which involves the reintroduction of specific effector cells into the patient bloodstream [273, 274]. Among them, Lymphokine Activated Killer Cells (LAK), Tumor-infiltrating lymphocytes (TILs) and Chimeric Antigen Receptors (CAR)-T cells are to be mentioned. Lymphokine Activated Killer Cells are obtained from the patient’s endogenous T cells, which are extracted, cultured in the presence of the lymphokine interleukin-2 (IL-2) and reinfused into the patient’s blood [275]. Tumor-infiltrating lymphocytes may have greater tumoricidal activity than LAKs, as they are isolated from resected tumor tissue, thus originating cells with greater tumor specificity than those obtained from blood [276]. An interesting method has recently been published by Ivovance Biotherapeutics, Inc., concerning the expansion of TILs from tumor cells using, among others, CD95 agonists, for the treatment of diseases such as cancer (WO2018129332) [277, 278, 366]. A more recent strategy has been developed on the idea of genetically modifying T cells to express TAA-specific T-Cell Receptors, or Chimeric Antigen Receptors that recognize specific proteins on the cancer cells surface. Lately, it has been shown that CAR-T cells up-regulate the expression of CD95 and CD95L resulting in activation of the cell death program independently of TCR or CAR antigen-mediated activation [279]. The work of the Donda’s team highlights the importance of the role of the CD95/CD95L system in CAR-T cells-induced apoptosis by demonstrating the rescue of CAR-T cells upon in vivo blockade of this death-signaling pathway by CD95-Fc recombinant proteins. Patent US20180088670, published in 2018 in the U.S., concerns a method using CAR-T cells to stimulate immunity towards tumor endothelial cells. It is known that one of the limitations of CAR-T cells includes the lack of ability for the T cells to infiltrate deep into tumor tissue. In this formulation CAR-T cells would be able to destroy the CD95L-positive tumor endothelial cells, but also survive in their presence [280]. A year later an American group made the observation that CD95 is highly expressed on patient-derived T cells used for clinical ACT (adoptive cell transfer). They elaborated a T-cell co-engineered system including CD95 DNR (Dominant Negative Receptor) and either a T-cell receptor or Chimeric Antigen Receptor. These cells were genetically modified to express a defective CD95 variant, impairing the induction of apoptotic signal, together with a Chimeric Antigen Receptor, resulting in superior antitumor efficacy, greater longevity and no observed autoimmunity [281]. An interesting observation was recently made by Joshua D Brody’s team, who found that the CD95/CD95L system, in addition to its antigen-specific T-cell killing capability, mediates off-target “bystander” killing of antigen-negative tumor cells. They propose that CD95-mediated bystander elimination of Ag-loss variants may already be occurring in CAR-T treated patients. This process appears to be induced by CD95 upregulation on tumor cells after exposure to T-cell-secreted IFN-γ. They developed a CAR-T mouse model showing an improvement in tumor clearance when CD95 signaling is intact [282]. Overall, these observations open the door to promising new therapeutic opportunities exploiting the CD95/CD95L system in the cancer immunotherapy context.

**THERAPEUTIC PERSPECTIVES IN CANCER**

It is well described that CD95 can promote pro-apoptotic and anti-apoptotic activities according to the physiological context [90]. Some previous studies have shown that down-regulating CD95 via shRNA in cancerous cells activates a death program by the induction of DNA damage and the activation of apoptotic effectors. One of these studies has been carried out and exposed in the US20100132116 patent, in which the inventors set out a siRNA-agent with the aim to reduce the amount of RNA encoding a CD95/CD95L gating polypeptides (e.g., FAP2 or PAT21 polypeptides) in significant quantities to sensitize brain tumor cells to CD95-mediated apoptosis [283, 284]. Over the past 25 years, several different potential therapeutic strategies related to the CD95/CD95L interaction have been studied. Among them, polypeptide systems, fusion proteins, methods, chemicals, antibiotics and drug delivery systems are probably the most extensively studied.

**Antitumoral polypeptides**

Few patents describing CD95-related polypeptides have been published to provide a different approach in cancer treatment. In 2015 it was observed that blood polymorphonuclear neutrophils (PMNs) could kill cancer cells with a mechanism that remains to be elucidated [285]. Last year, a new method for reducing the toxicity of anticancer treatment on normal or non-cancerous cells has been registered as a patent at the University of Chicago (WO2020132465). This invention showed that ELANE, identified as the major antitumour protein released by PMNs, could cleave the CD95 receptor, releasing an intracellular proteolytic fragment containing the Death Domain and selectively killing a wide range of cancer cells [286]. The invention is a combination of specific CD95 peptides and the DNA encoding these peptides to treat different types of cancer. As previously mentioned, metalloproteases-cleaved CD95L (sCD95L) result in the pro-oncogenic activity, through its interaction with CD95, promoting the survival and proliferation of cancer cells, but also their dissemination [141]. Therefore, a group proposed (WO2015155810) the use of polypeptides composed of the amino acid sequence encompassing the intracellular domain of CD95 which they previously identified as inducing a calcium-dependent cell motility process in T lymphocytes [145]. These inventors reported that the use of such peptides prevented the activation of PLCγ1 and the consequent calcium response that leads to cell
migration. The same group reported a few years later that five molecules selected from the FDA/EMA-approved chemical library, namely Ritonavir, Diflunisal, Anethole, Rosiglitazone and Daunorubicin, could all block the recruitment of PLCγ1 to CD95 and reduce T lymphocyte motility (WO2018130679). Less recently, Wagner and Wei published a method related to the use of a combination of polypeptides and their encoding nucleotide (WO2008067305) [287, 288]. They proposed a polypeptide composed of a ligand domain for a stimulatory Natural Killer receptor (e.g., the extracellular domain of MULT-I, which binds the NK cells receptor NKG2D) and the CD95 intracytoplasmic death domain. This method is supposed to activate the NK cells through the NKG2D receptor after contact with the tumor cells expressing the polypeptidic fusion compound so that not only the engaged tumor cells will be killed via CD95 induced-mechanisms but also are lysed directly by the activated NK cells.

CD95-related chimeric proteins

Another similar therapeutic approach related to the CD95/CD95L system for the treatment of cancer is the use of fusion proteins or chimeric proteins. Since the years 2000s, the fusion protein system has been perhaps the most widely studied. Patent WO2014121093 should be mentioned among the most recent of them [289]. Here, the inventors elaborated a chimeric system composed of a component capable of inducing the CD95-mediated apoptotic signal, and a component capable of blocking the CD47 receptor expressed at the tumor cell membrane and involved in the suppression of macrophage phagocytosis of the tumor cells. The approach concerning fusion proteins that provide a physiologically similar oligomerized form of CD95L was studied by two different groups. One exposed a bi-component protein comprising the CTLA-4 extracellular domain and the CD95L extracellular domain, present in the form of a covalently bound and stable homo-hexamer, suitable for the treatment of a patient with cancer (WO2014106839) [350, 351]. If said patient has a tumor expressing the B7 receptor (e.g., B-cell lymphoma), this compound should be administered to exploit the double affinity of the bi-protein for the B7 and CD95 receptors, and finally inducing apoptosis of the malignant cells. The second group instead describes a chimeric protein composed of the extracellular domain of CD95L and a domain capable of inducing the oligomerization in this chimeric system (WO2013060864) [292–294]. Said domain is represented by the Ig-like domain of the Leukemia Inhibitory Factor (LIF) receptor gp190, which self-associates in the context of the chimeric protein giving rise to a dodecameric form with cytotoxic activity towards the cells expressing CD95. This system could therefore have various applications in the clinical field for the treatment of various diseases, such as cancer, autoimmune diseases and others.

Innovative antitumoral methods

The innovative methods approached in the context of the treatment of cancer patients are numerous and varied, among the most recent of which are the patents WO2015189236, WO2015104284, and WO2014118317, all filed and published by the same group. The first concerns a method aimed to reduce CD95-induced cell migration (WO2015189236). NHE1 is a Na+/H+ exchanger channel which this group reported to be indispensable for the CD95-induced cell motility process in fibroblasts [295]. This invention provides pharmaceutical compositions of compounds with NHE1 inhibiting properties to be administered if the subject shows elevated blood levels of sCD95L. This group also reported that in triple-negative breast cancer (TNBC), the serum level of CD95L could constitute an important parameter for the prognosis of the survival time and/or the relapse-free survival time. The same group therefore patented the invention WO2015104284, which aims to first determine the expression of sCD95L in the serum of subjects with triple-negative breast cancer (TNBC) and then to compare this level of expression to a predetermined standard value. The concluding step involves the administration to said subject of an effective therapeutic dose of plasma membranes structural components. The goal is to reduce the fluidity of the plasma membrane, a factor that this group reported as involved in the induction of cell migration by CD95 [296]. Subsequently, this same research group developed another patent, this time concerning the prediction and prevention of metastases in TNBC (WO2014118317). The authors describe a method for identifying serum levels of sCD95L in TNBC patients, stating that these patients develop a high risk of relapse if the level of sCD95L is significantly higher than a standard expression level [141]. In the same couple of years, another inventor published a method for predicting the sensitivity of tumor cells for a given treatment targeting inhibition of the CD95/CD95L system (WO2015107105) [297–299]. The invention more specifically concerns the analysis of the methylation levels of a DNA sequence of a gene belonging to this apoptotic signaling cascade obtained directly from a subject suffering from cancer, and consequent observation on the possible responsiveness of said cancer cells to a specific treatment. DNA and histone modifications remain the two major mechanisms of epigenetic regulation of gene expression [300]. Some inhibitors of these mechanisms, such as Decitabine and Vorinostat, are currently in clinical use to inhibit DNA methylation and histone acetylation respectively. An equally important role in the regulation of gene expression is played by the methylation of histone lysine residues through the action of Histone Methyltransferase (HMTase), for which to date only two chemical inhibitors (Verticillin A and Chaetocin) have been generated and found to be toxic in vivo. The Augusta University Research Institute, Inc. has developed a new inhibitor for HMTase SUV39H1 that appears to be useful in activating certain cytotoxic T-cell effectors, such as CD95L, thereby reversing cancer-induced immune suppression and promoting the killing of cancer cells by cytotoxic T cells (US20190084987) [301].

CURRENTLY USED THERAPIES AND THERAPEUTIC PERSPECTIVES IN AUTOIMMUNE DISEASES

Despite our growing knowledge of the immunological abnormalities that can lead to autoimmunity, the etiologies of most human autoimmune diseases remain unclear. This is probably because human autoimmune diseases are generally heterogeneous and multifactorial, not only between different diseases but also within the same disease [302]. They can, within a single disease, present a wide variety of clinical manifestations and severity, for instance the propagation speed, the number of affected joints, as well as a vast phenotypic heterogeneity. Besides, autoimmune diseases can clinically manifest long after the autoimmune reactions have been induced. Autoimmune diseases are often characterized by a severe imbalance between pro and anti-inflammatory mechanisms and by a vast diversity of signaling pathways and of cells and cytokines such as interleukins, interferons, and Treg cells that play a crucial role in immune tolerance. In recent decades, enormous progress has been made to identify the mechanisms associated with the activation and inactivation of T cells and to improve techniques based on the study of selective immune suppression in human autoimmune diseases. To date, the techniques used to counteract the mechanisms of autoimmunity are varied and include different peptide analogs, immunosuppressants, anti-inflammatory, monoclonal antibodies, inducers of immune tolerance, therapies targeting certain autoantigens, often used in conjunction with immunosuppressants to reduce their doses. Several groups around the world have carried out studies for which patents have been filed.

Multiple sclerosis

MS is a chronic autoimmune neurodegenerative disease that affects the central nervous system (CNS). It is characterized by an
abnormal reaction of the immune defenses towards certain components of the CNS, damaging myelin and oligodendrocytes [303]. The symptoms are varied but CNS defective functions are frequent, with recurrent remissions and exacerbations. MS is suspected in patients with optic neuritis, especially if the deficits are multifocal or intermittent. In such cases, magnetic resonance imaging (MRI) scans of the brain and spinal cord and cerebrospinal fluid (CSF) analyses are performed, as this techniques allow to exclude other treatable pathologies that can mimic MS [304]. At the moment there is no definitive cure, but numerous therapies are available to modify its course, slowing its progression. The most severe form of MS is undoubtedly represented by relapsing-remitting multiple sclerosis (RMSR). Subjects with RMSR tend to have more brain lesions with widely varying localization and very different symptoms [305]. To date, the diagnosis to confirm the presence of the disease is given by tests resulting positive at least on two areas of myelin lesions in the CNS. These tests are not only painful but also risky and highly expensive. It is, therefore, necessary to develop additional methods for the diagnosis of this disease. The inventors of US20160194714 offer a new method for detecting relapse in RMSR patients using biomarkers, such as CD95L, sirtuin 1 (SIRT1), RGC-32 and IL-21, in a population of cells detecting relapse in RRMS patients using biomarkers, such as discordant results on CD95L expression levels in total lymphocytes [314].

was associated with lower expression of CD95L and overexpression of IL-21 versus HCs (Healthy Controls), which also differ in their sensitivity to TCR-mediated cell death [310–313]. This could explain the discordant results on CD95L expression levels in total lymphocytes from healthy donors and patients with chronic inflammatory disease. A few years ago, it was noted that transcription of CD95L is crucial for the regulation of T-helper cell death sensitivity. This group found that human Th1 cells express higher mRNA levels of CD95L than Th17 cells. Resistance of Th17 cells to AICD was associated with lower expression of CD95L and overexpression of the anti-apoptotic caspase-8 inhibitory protein (FLIP) [314]. In the mid-2000s, an important role was attributed to these IL-17A and IL-17F producing lymphocytes in the context of autoimmune diseases. Th17 cells orchestrate autoimmune inflammation, in addition to their function as eliminators of extracellular pathogens [315–317]. Yang et al. observed that SLE patients exhibit significant infiltration of Th17 lymphocytes secreting cytokines in their skin [318]. It is therefore possible to hypothesize that by modulating their trafficking to the organs, the pathogenesis of the SLE disease could consequently be modulated. In the context of this chronic inflammatory disease, soluble CD95L (sCD95L) has been shown to be involved in promoting the trafficking of Th17 lymphocytes into damaged organs, at the expense of Treg lymphocytes in a CD95-driven murine model of SLE [142]. Blocking the CD95/CD95L system could thus represent an attractive approach for the treatment of Th17 cell-mediated diseases. This was the intent of the authors of the WO20161700272, who proposed to use CD95 antagonist antibodies, having specificity for CD95 or sCD95L, with the potential to prevent the endothelial transmigration of Th17 cells in the organs and the consequent damage given by the accumulation of the activated T cells in said organs [142]. DR-mediated cell death is essential for the differentiation, growth and function of lymphocytes. In 2017, Croft and Siegel discussed the implication of some of these receptors in inducing inflammation and their potential in future therapies for rheumatoid diseases [319]. Interestingly, the combined blockade of TNFR1, TRAIL-R and CD95 seems to give excellent results in the prevention of inflammation caused by the respective ligands, whereas targeting these receptors individually did not have that effect (WO2019141862) as demonstrated in a murine model of dermatitis [320]. Such observations lead to the conclusion that different cell DR systems may act in combination to contribute to the pathogenesis of autoimmune inflammatory diseases. Importantly, uncontrolled induction of cell death downstream of DR, rather than increased DR-induced gene-activatory signaling pathways, could actually be key in driving inflammation in such contexts [320–322]. Interestingly, the Decay Receptor 3 (Dr3), encoded by the TNFRSF68 gene, was found to act as a regulator of the amplification of the immune response by binding with stimulatory cytokines, such as CD95L, TL1A and LIGH, limiting the interaction of the latter with their own receptor [323]. It, therefore, seems deductible that genetic modifications of the TNFRSF68 gene, involving a reduced expression of Dr3, or a lower binding activity for the aforementioned cytokine, or even the suppression of its expression, could contribute to cause inflammatory signals. With this idea in view, the inventors of US20170051352 have developed a method for treating autoimmune conditions in patients carrying alterations of the gene encoding the Dr3 protein, or of a Dr3 network gene, by administering to said patient an effective amount of Dr3 ligands inhibitors [323].

Fusion proteins in the context of autoimmune diseases

As in the context of cancer, one of the widely adopted strategies in studying new potential treatments for autoimmune diseases is represented by the use of fusion proteins and nucleotides that encode them. In 2018, APOGENIX AG published a patent relating to a nucleotide sequence encoding an isolated chimERIC compound formed by the extracellular domain of CD95 and an immunoglobulin domain or a functional fragment thereof. The inventors intend to generate a stable system to inhibit the extrinsic apoptotic signal initiated by CD95L for the prophylaxis or treatment of various diseases, including autoimmune diseases and solid cancers (US20180186856) [324, 325, 402]. A few years earlier the same inventors developed a mixture of fusion protein isoforms having the same composition as the aforementioned system with the difference that this patent does not mention any nucleotide sequence encoding the chimERIC protein, as well as the cell hosting the nucleotide sequence (WO2014013039). A different chimERIC system is represented by the invention WO2016205714, which exposes an immune tolerance inducer “medicament” comprising a CD95L moiety together with a streptavidin or avidin moiety [326–328]. The claimed compound is to be administered alone or mixed with the IL-2 protein to achieve sequential or simultaneous action in inducing long-term and specific immunosuppression. CD95L is then part of another fusion compound, the one described by the patent WO2014121085, in which the extracellular domain of CD95L corresponds to half of the fusion protein. The other half is the extracellular domain of a PD-1 receptor-activating factor, such as its ligand PD-L1 and PD-L2 [329]. This system aims to inhibit the differentiation and proliferation of a selection of cells, including activated T cells on which the PD-1 receptor is widely expressed, thus the induction of PD-1 ligation by its ligands mediates an inhibitory signal that results in reduced cytokine production and reduced T-cell survival. Thus, in the setting of autoimmune and inflammatory diseases, the fusion protein of this invention could reduce autoimmune and inflammatory manifestations.

Cells engineering modifications

Some other groups have then explored the field of cells engineering modification by proposing methods of isolating these cells from a patient sample, treating/modifying these cells and reintroducing the said modified cells by systemic infusion or
DISCUSSION AND CONCLUSION

For nearly three decades, members of the TNF superfamily, and the signal cascades they trigger, have been targeted by researchers and pharmaceutical companies to develop new therapies for the treatment of cancer and autoimmune diseases [334–338]. These molecules are widely involved in multiple cellular mechanisms such as apoptosis, proliferation, survival, tumor growth and differentiation. Since their role in mediating immune surveillance as well as protection from infections is essential, prolonged inhibition of these molecules could be dangerous. The progenitor of the TNF superfamily (i.e., TNF) remains the most studied and the most promising in terms of therapeutic potential [337, 338]. Among the members of the TNF superfamily, the research carried out on the TNF system is the most funded, with sales revenues exceeding 25 billion USD [338] followed by DR4/DR5 (Trail) systems and finally by the CD95 complex. Currently, five anti-TNF biologics have been clinically approved for the treatment of autoimmune diseases, namely Infliximab, Adalimumab, Etanercept, Golimumab, and Certolizumab Pegol, all with a specific structure for TNF-alpha recognition and blockade [339]. Despite the evident efficacy of these drugs, not all treated patients respond as expected and some seem to develop adverse reactions associated with these drugs, such as effects on the neurological and dermatological levels [340–342]. There is therefore a growing need for new pharmacological systems with better specificity and greater safety.

CD95-related therapeutic perspectives

Despite the evident role of CD95/CD95L in cancer and chronic inflammatory autoimmune diseases, since 1990 only a little over a hundred patents targeting the CD95/CD95L system have been conceived and published (Fig. 4). In the past, the complexity of the multiple CD95/CD95L-mediated signaling systems found in cancer and autoimmune diseases, the lack of specificity of the previously proposed strategies tested in vivo and the consequent severe side effects found [219, 220], have diminished the pharmacological interest for this target. Recent study report strategies focusing on more challenging compounds and delivery methods, with a particular attention to circumventing the severe adverse effects associated with the systemic activation of CD95. The extensively studied CD95-Fc fusion proteins, for instance, represent an interesting way to inhibit CD95L. However, these chimeric proteins, compared to those used in the TNF-TNFR2 system [343], exhibit a relatively low affinity for the corresponding CD95L and far less efficacy in inhibiting death induced by ligand interaction with CD95. A possible explanation is given by the fact that the interactions between these proteins occur through a complex mechanism of oligomerization given by the association of multiple trimers of both counterparts [35, 294, 344]. A better neutralization or stimulation of these proteins might therefore be achieved by a neutralization/stimulation system in which the binding protein is in a stable physiological-like form consisting of at least one trimer, if not an oligomer thereof. It seems that the oligomerization of the binding protein improves the stability of the therapeutic compound, consequently increasing its affinity for the target and the final system specificity [345]. Such oligomerized-related strategies have exhibited more efficient results, compared to previous systems generations. Fortunately, some of the newly proposed strategies appear to give encouraging preclinical results and so far, only one of these is currently in clinical trials. APG101 is the best prototype of future therapeutic approaches involving the CD95 system. It is an 84 kDa CD95L-neutralizing CD95 trimer fusion protein, able to pass the blood-brain barrier. Asunercept, the trade name for APG101, is now the subject of a controlled phase II clinical trial in patients with relapsed glioblastoma multiforme (GBM) (NCT01071837). The
Cell Death and Disease (2022) 13:248

V. Risso et al.

89. Singh R, Letai A, Sarosiek K. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat Rev Mol Cell Biol. 2019;20:175–93.

90. White MJ, McArthur K, Metcalf D, Lane RM, Cambier JC, Herald MJ, et al. Apoptotic caspases suppress mtDNA-induced STING-mediated type I IFN production. Cell. 2014;159:1549–62.

91. Rongvaux A, Jackson R, Harman CCD, Li T, West AP, De Zoete MR, et al. Apoptotic caspases prevent the induction of type I interferons by mitochondrial DNA. Cell. 2014;159:1563–77.

92. Giampazolias E, Zunino B, Dhayade S, Bock F, Cloix C, Cao K, et al. Mitochondrial permeabilization engages NF-kB-dependent anti-tumour activity under caspase deficiency. Nat Cell Biol. 2017;19:1116–29.

93. Diepstraten ST, Anderson MA, Czabotar PE, Lessene G, Alnemri ES, et al. Manipulation of apoptosis for cancer therapy using BH3-mimetic drugs. Nat Rev Cancer. 2021.https://doi.org/10.1038/S41568-021-00407-4.

94. Feinstein E, Kinchi A, Wallach D, Boldin M, Varfolomeev E. The death domain: a module shared by proteins with diverse cellular functions. Trends Biochem Sci. 1995;20:342–4.

95. Papoff G, Hausler P, Erano A, Pagano MG, Lev G, Signore A, et al. Identification and characterization of a ligand-independent oligomerization domain in the extracellular region of the CD95 death receptor. J Biol Chem. 1999;274:38241–50.
36. Siegel RM, Frederiksen JK, Zacharias DA, Chan FKM, Johnson M, Lynch D, et al. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science. 2000;288:2354–7.

37. Steller EJ, Borel Rinkes IHM, Kranenburg O. How CD95 stimulates invasion. Cell Cycle. 2011;10:1857–62.

38. Berg D, Lehne M, Müller N, Siegmund D, Münkel S, Sebalb W, et al. Enforced coexpression of TNFR1 increases the activity of the TNF ligand family members TRAIL and CD95L. Cell Death Differ. 2007;14:2021–34.

39. Sun M, Ames KT, Suzuki I, Fink PJ. The cytoplasmic domain of fas ligand costi-
mulates TCR signals. J Immunol. 2000;167:1481–91.

40. Suzuki I, Martin S, Boursalian TE, Beers C, Fink PJ. Fas ligand costimulates the in vivo proliferation of CD8+ T cells. J Immunol. 2000;165:5537–43.

41. Desbarats J, Duke RC, Newell MK. Newly discovered role for caspase-8 in the cell-cycle arrest of CD4+ T cells. Nat Med. 1998;4:1377–82.

42. Paulsen M, Mathew B, Qian J, Lettau M, Janssen O. FasL cross-linking regulates TCR signals: novel cytoplasmic structures that recruit caspases and trigger apoptosis. J Immunol. 2009;201:587–98.

43. Fu Q, Fu TM, Cruz AC, Sengupta P, Thomas SK, Wang S, et al. Structural basis and functional role of intramembrane trimerization of the Fas/CD95 death receptor. Mol Cell. 2016;61:602–13.

44. Kischkel FC, Hellbardt S, Behrmann I, Germer M, Pawlita M, Krammer PH, et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 1995;14:5579–88.

45. Scott FL, Ster C, Pop C, Dobaczewska MK, Lee JJ, Monosov E, et al. The Fas-FADD death domain complex structure unravels signalling by receptor clustering. Nature. 2009;457:1019–26.

46. Siegel RM, Muppidi JR, Sarker M, Lobito A, Jen M, Martin D, et al. SPOTS: signaling protein oligomeric transduction structures are early mediators of death receptor-induced apoptosis at the plasma membrane. J Cell Biol. 2004;167:745–55.

47. Mahdizadeh SJ, Thomas M, Eriksson LA. Reconstruction of the fas-based death-inducing signaling complex (DISC) using a protein-protein docking meta-
approach. J Chem Inf Model. 2021;61:3543–58.

48. Chinnayya AM, Tepper CG, Seldin MF, O’Rourke K, Kischkel FC, Hellbardt S, et al. FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis. J Biol Chem. 1996;271:4961–5.

49. Yeh WC, De La Pompa JL, McCurrach ME, Shahinian A, et al. FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science. 1998;279:1954–8.

50. Siegel RM, Martin DA, Zheng L, Ng SY, Bertin J, Cohen J, et al. Cell death effector filaments: novel cytoplasmic structures that recruit caspases and trigger apoptosis. J Cell Biol. 1998;141:1243–53.

51. Dickens LS, Boyd RS, Jukes-Jones R, Hughes MA, Robinson GL, Fairall L, et al. A death effector domain chain DISC model reveals a crucial role for caspase-8 chain assembly in mediating apoptotic cell death. Mol Cell. 2012;47:291–305.

52. Schlech K, Warnken U, Münkel S, Sebalb W, et al. Stoichiometry of the CD95 death-inducing signaling complex: experimental and modeling evidence for a death effector domain chain model. Mol Cell. 2012;47:306–19.

53. Fu TM, Li Y, Lu A, Li Z, Vajjhala PR, Cruz AC, et al. Cryo-EM structural analysis of FADD:Caspase-8 complexes de-
999;21:2866.

54. Tenev T, Bianchi K, Darding M, Broemer M, Langlais C, Wallberg F, et al. The death-inducing signaling complex (DISC) using a protein-protein docking meta-
approach explains how FLP1(L) can inhibit or promote apoptosis. EMBO Rep. 2020;21.https://doi.org/10.15252/EMBR.201949254.

55. Boatright KM, Des C, Renaut J, Sutherlin DP, Salvesen GS. Activation of caspases-8 and -10 by FADD/FLIP. Biochem J. 2004;382:651–7.

56. Kischkel FC, Lawrence DA, Tinel A, LeBlanc H, Virmani A, Schow P, et al. Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J Biol Chem. 2001;276:46639–46.

57. Sprick MR, Rieser E, Stahl H, Grosse-Wilde A, Weigand MA, Walczak H. Caspase-8 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8. EMBO J. 2002;21:4520–30.

58. Sakamaki K, Imai K, Tomi K, Miller DJ. Evolutionary analyses of caspase-8 and its paralogs: deep origins of the apoptotic signaling pathways. BioEssays. 2015;37:767–76.

59. Fischer U, Stroh C, Schulze-Osthoff K. Unique and overlapping substrate spe-
cificities of caspase-8 and caspase-10. Oncogene. 2006;25:152–9.

60. Lafont E, Milhas D, Tessié J, Therville N, Andrieu-Abadie N, Levade T, et al. Caspase-10-dependent cell death in Fas/CD95 signalling is not abrogated by caspase inhibitor z-VAD-fmk. PloS ONE. 2010;5.https://doi.org/10.1371/JOURNAL.PONE.0013638.

61. Backus KM, Correia BE, Lum KM, Fori S, Horning BD, González-Páez GE, et al. Proteome-wide covalent ligand discovery in native biological systems. Nature. 2016;534:570–4.

62. Milhas D, Cuvillier O, Therville N, Clave P, Thomsen M, Levade T, et al. Caspase-10 triggers Bid cleavage and caspase cascade activation in Fas-induced apoptosis. J Biol Chem. 2005;280:19836–42.

63. Engels RH, Tötzke G, Fischer U, Schulze-Osthoff K, Jänicek RU. Caspase-10 sensitizes breast carcinoma cells to TRAIL-induced but not tumor necrosis factor-induced apoptosis in a caspase-3-dependent manner. Mol Biol Cell. 2005;16:2808–18.

64. Wang J, Chun HU, Wong W, Spencer DM, Lenardo MJ. Caspase-10 is an initiator caspase in death receptor signaling. Proc Natl Acad Sci USA. 2001;98:13884–8.

65. Hughes MA, Kischkel FC, Schilling R, Sticht C, Tenev T, Poessler M, et al. Caspase-10 negatively regulates caspase-8-mediated cell death, switching the response to CD95 in favor of NF-κB activation and cell survival. Cell Rep. 2017;19:785–97.

66. Mühlthaler-Mottet A, Flahaut M, Balsam B, Focault R, Keldjor J, Koval C, Liberman J, et al. Individual caspase-10 isoforms play distinct and opposing roles in the initiation of death receptor-mediated tumour cell apoptosis. Cell Death Dis. 2011;2.https://doi.org/10.1038/CDDIS.2011.8.

67. Scafaro AM, Litchfield A, Richter M, Márquez VE, Scheel M, et al. Decoding the sweet regulation of apoptosis: the role of glycosylation and galectins in apoptotic signaling pathways. Cell Death Differ. 2019;26:981–93.

68. Lafont E, Hartwig T, Walczak H. Paving TRAIL’s path with ubiquitin. Trends Biochem Sci. 2018;43:44–60.

69. Seyrek K, Richter M, Lavrkin IN. Decoding the sweet regulation of apoptosis: the role of glycosylation and galectins in apoptotic signaling pathways. Cell Death Differ. 2019;26:981–93.

70. Chen L, Park SM, Tumavan AV, Hau A, Sawada K, Feig E, et al. CD95 promotes tumour growth. Nature. 2010;465:492–6.
100. Tauzin S, Debure L, Moreau JF, Legembre P. CD95-mediated cell signaling in cancer. Cell Death Differ. 2011;18:549–59.

101. Martin DA, Zheng L, Siegel RM, Huang B, Fisher GH, Wang J, et al. Defective Fas (Apo-1/CD95) gene in cutaneous malignant melanoma. Am J Pathol. 1999;154:1785–91.

102. Lee SH, Shin MS, Park WS, Kim SY, Kim HS, Han JY, et al. Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer. Oncogene. 1999;18:3754–60.

103. Park S, Oh R, Kim YS, Park Y, Lee H, Shin MS, et al. Somatic mutations in the death domain of the Fas (Apo-1/CD95) gene in gastric cancer. J Pathol. 2003;201:1362–6.

104. Martin DA, Zheng L, Siegel RM, Huang B, Fisher GH, Wang J, et al. Defective Fas (Apo-1/CD95) gene in transitional cell carcinomas of urinary bladder. Cancer Res. 1999;59:3068–72.

105. Park S, Oh R, Kim YS, Park Y, Lee H, Shin MS, et al. Somatic mutations in the death domain of the Fas (Apo-1/CD95) gene in gastric cancer. J Pathol. 2003;201:1362–6.

106. Tsao SJ, Deverue L, Moreau JF, Legembre P. CD95-mediated cell signaling in cancer: mutations and post-translational modifications. Cell Mol Life Sci. 2012;69:1261–77.

107. Poissonnier A, Guelgan JP, Nguyen HT, Best D, Levoinn N, Kozlov G, et al. Disrupting the CD95–FLC-190 interaction prevents Th17-driven inflammation. Nat Chem Biol. 2014;10:799–808.

108. Martin DA, Zheng L, Siegel RM, Huang B, Fisher GH, Wang J, et al. Defective Fas (Apo-1/CD95) gene in transitional cell carcinomas of urinary bladder. Cancer Res. 1999;59:3068–72.

109. Lee SH, Shin MS, Park WS, Kim SY, Kim HS, Han JY, et al. Alterations of Fas (Apo-1/CD95) gene in transitional cell carcinomas of urinary bladder. Cancer Res. 1999;59:3068–72.

110. Wajant H, Haas E, Schwenzer R, Muhlenbeck F, Kreuz S, Schubert G, et al. NF-kappaB regulates the CD95-mediated apoptosis pathway. J Biol Chem. 2006;281:1840–52.

111. Kreuz S, Siegmund D, Scheurich P, Wajant H. NF-kappaB induces upregulation of c-FLIP, a cycloheximide-sensitive inhibitor of death receptor signaling. Mol Cell Biol. 2001;21:3964–73.

112. Mischeau O, Lens S, Gaide O, Alevizopoulos K, Tschopf J. NF-kappaB signals induce the expression of c-FLIP. Mol Cell Biol. 2001;21:5299–305.

113. Shinohara H, Yagita H, Ikawa Y, Oyayu N. Fas drives cell cycle progression in glioma cells via extracellular signal-regulated kinase activation. Cancer Res. 2000;60:1766–72.

114. Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Anticancer Res. 2003;23:3311–6.

115. Roux BP, Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev. 2004;68:3220–44.

116. Krens SFG, Spahn HF, Snaar-Jagalska BE. Functions of the Fas family in vertebrate development. FEBS Lett. 2006;580:4964–90.

117. Yang X, Kharov-Far R, Chang HY, Baltimore D. Daxx, a novel Fas-binding protein that activates JNK and apoptosis. Cell. 1997;89:1067–76.

118. Xu R, Hu J. The role of JNK in prostate cancer progression and therapeutic strategies. Biomedicine Pharmacother. 2020;121:109679.

119. Kim YY, Park BJ, Seo GJ, Lim JY, Lee SM, Kimm KC, et al. Long form of cellular FLICE-inhibitory protein interacts with Daxx and prevents Fas-induced JNK activation. Biochem Biophys Res Commun. 2003;312:426–33.

120. Deak JC, Cross JV, Lewis M, Qian Y, Parrott LA, Distelhorst CW, et al. Fas-induced proteolytic activation and intracellular redistribution of the stress-signaling kinase MEK1K1. Proc Natl Acad Sci USA. 1998;95:5595–600.

121. Kuruvik SM, Gereserik P, Berg D, Dimitrova DP, Feoktistova M, Siegmund D, et al. Cellular FLICE-inhibitory protein (c-FLIP) isoforms block CD95- and TRAIL death receptor-induced gene induction irrespective of processing of caspase-8 or c-FLIP in the death-inducing signaling complex. J Biol Chem. 2011;286:16631–46.

122. Ahn JH, Park SM, Cho HS, Lee SM, Yoon JB, Vilecek J, et al. Non-apoptotic signaling pathways activated by soluble Fas ligand in serum-starved human fibroblasts. Mitogen-activated protein kinases and NF-kappaB-dependent gene expression. J Biol Chem. 2001;276:47100–6.

123. Desbarats J, Birge RB, Mimmoun-Rongy M, Weinstein DE, Palerme JS, Newell MW. Fas engagement induces neurite growth through ERK activation and p35 upregulation. Nat Cell Biol. 2003;5:118–25.

124. Siegmund D, Klose S, Zhou D, Baumann B, Roder C, Kalthoff H, et al. Role of caspases in CD95L- and TRAIL-induced non-apoptotic signaling in pancreatic cancer cells. Cell Signal. 2001;13:717–22.

125. Farley SM, Purdy DE, Ryabinina OP, Schneider P, Magun BE, Iordanov MS. Fas ligand-induced proteolytic activation and intracellular redistribution of the stress-signaling kinase MEK1K1. Proc Natl Acad Sci USA. 1998;95:5595–600.

126. Krens SFG, Spahn HF, Snaar-Jagalska BE. Functions of the Fas family in vertebrate development. FEBS Lett. 2006;580:4964–90.

127. Yang X, Kharov-Far R, Chang HY, Baltimore D. Daxx, a novel Fas-binding protein that activates JNK and apoptosis. Cell. 1997;89:1067–76.

128. Xu R, Hu J. The role of JNK in prostate cancer progression and therapeutic strategies. Biomedicine Pharmacother. 2020;121:109679.

129. Kim YY, Park BJ, Seo GJ, Lim JY, Lee SM, Kimm KC, et al. Long form of cellular FLICE-inhibitory protein interacts with Daxx and prevents Fas-induced JNK activation. Biochem Biophys Res Commun. 2003;312:426–33.

130. Deak JC, Cross JV, Lewis M, Qian Y, Parrott LA, Distelhorst CW, et al. Fas-induced proteolytic activation and intracellular redistribution of the stress-signaling kinase MEK1K1. Proc Natl Acad Sci USA. 1998;95:5595–600.

131. Kuruvik SM, Gereserik P, Berg D, Dimitrova DP, Feoktistova M, Siegmund D, et al. Cellular FLICE-inhibitory protein (c-FLIP) isoforms block CD95- and TRAIL death receptor-induced gene induction irrespective of processing of caspase-8 or c-FLIP in the death-inducing signaling complex. J Biol Chem. 2011;286:16631–46.

132. Ahn JH, Park SM, Cho HS, Lee SM, Yoon JB, Vilecek J, et al. Non-apoptotic signaling pathways activated by soluble Fas ligand in serum-starved human fibroblasts. Mitogen-activated protein kinases and NF-kappaB-dependent gene expression. J Biol Chem. 2001;276:47100–6.

133. Desbarats J, Birge RB, Mimmoun-Rongy M, Weinstein DE, Palerme JS, Newell MW. Fas engagement induces neurite growth through ERK activation and p35 upregulation. Nat Cell Biol. 2003;5:118–25.

134. Siemund D, Klose S, Zhou D, Baumann B, Roder C, Kalthoff H, et al. Role of caspases in CD95L- and TRAIL-induced non-apoptotic signaling in pancreatic cancer cells. Cell Signal. 2001;13:717–22.

135. Farley SM, Purdy DE, Ryabinina OP, Schneider P, Magun BE, Iordanov MS. Fas ligand-induced proteolytic activation and intracellular redistribution of the stress-signaling kinase MEK1K1. Proc Natl Acad Sci USA. 1998;95:5595–600.

136. Krens SFG, Spahn HF, Snaar-Jagalska BE. Functions of the Fas family in vertebrate development. FEBS Lett. 2006;580:4964–90.

137. Yang X, Kharov-Far R, Chang HY, Baltimore D. Daxx, a novel Fas-binding protein that activates JNK and apoptosis. Cell. 1997;89:1067–76.

138. Xu R, Hu J. The role of JNK in prostate cancer progression and therapeutic strategies. Biomedicine Pharmacother. 2020;121:109679.

139. Kim YY, Park BJ, Seo GJ, Lim JY, Lee SM, Kimm KC, et al. Long form of cellular FLICE-inhibitory protein interacts with Daxx and prevents Fas-induced JNK activation. Biochem Biophys Res Commun. 2003;312:426–33.
140. Schulte M, Reiss K, Lettau M, Maretsky T, Ludwig A, Hartmann D, et al. ADAM10 regulates FasL cell surface expression and modulates FasL-induced cytotoxicity and activation-induced cell death. Cell Death Differ. 2007;14:1040–9.

141. Mallette M, Tazou S, Bessede A, Castellano R, Goubard A, Godsey F, et al. CD95L cell surface cleavage triggers a prometastatic signaling pathway in triple-negative breast cancer. Cancer Res. 2013;73:6711–21.

142. Pouloumi O, Assafou A, Sansal N. CD95L signaling promotes T helper 17 trafficking to inflamed organs in lupus-prone mice. Immunity. 2016;45:209–23.

143. Sudha T, Hashimoto H, Tanaka M, Ochi T, Nagata S. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med. 1997;186:2045–50.

144. Schneider P, Holler N, Bodmer J-L, Hahne M, Frei K, Fontana A, et al. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med. 1998;187:1205–13.

145. Tazou S, Chaigne-Delalande B, Selva E, Khadra N, Daburon S, Contin-Bordes C, et al. The Naturally Processed CD95L Elicits a c-Yes/Calcium/Pi3K-Driven Cell Migration Pathway. PLoS Biol. 2011;9:e1001090.

146. Le Gallo M, Paussonnier A, Blanco P, Legembre P. CD95/Fas, non-apoptotic signaling pathways, and kinases. Front Immunol. 2017;8. https://doi.org/10.3389/fimmu.2017.01216.

147. O’Reilly LA, Tai L, Lee E, Kruse EA, Grabow S, Fairlie WD, et al. Membrane-bound Fas only is essential for Fas-mediated apoptosis. Nature. 2009;461:659–63.

148. Ehrenschwender M, Siegmund D, Wicovsky A, Kracht M, Dittrich-Breiholz O, Spindler V, et al. Mutant PIK3CA licenses TRAIL and CD95L to induce non-apoptotic caspase-8-mediated ROCK activation. Cell Death Differ. 2010;17:1435–47.

149. Cursi S, Ruth PF, Datta A, Wang Q, Reilly LA, Bouillet P. What do we know about the Fas ligand. Cell Death and Disease. 2020;11:627.

150. Wang L, Wang FS, Gershwin ME. Human autoimmune diseases: a comprehensive update. J Intern Med. 2015;278:369–81.

151. Senft J, Helfer B, Frisch SM. Caspase-8 interacts with the p85 subunit of phosphatidylinositol 3-kinase to regulate cell adhesion and motility. Cancer Res. 2001;61:4955–60.

152. Le Gallo M, Paussonnier A, Blanco P, Legembre P. CD95/Fas, non-apoptotic signaling pathways, and kinases. Front Immunol. 2017;8. https://doi.org/10.3389/fimmu.2017.01216.

153. Reilly LA, Bouillet P. What do we know about the Fas ligand. Cell Death and Disease. 2020;11:627.

154. Wang L, Wang FS, Gershwin ME. Human autoimmune diseases: a comprehensive update. J Intern Med. 2015;278:369–81.

155. Bouillet P, O'Reilly LA. CD95, BIM and T cell homeostasis. Nat Rev Immunol. 2009;9:514–9.

156. Xing Y, Hoggquist KA. T-cell tolerance: central and peripheral. Cold Spring Harb Cell Biol. 2001;2:917–23.

157. Gururajan M, Sindhava VJ, Bondada S. B cell tolerance in health and disease. Immunol Cell Biol. 2008;86:57–63.

158. Powley IR, Hughes MA, Cain K, MaCfarlane M. Caspase-8 tyrosine-380 phosphorylation inhibits CD95 DISC function by preventing procaspase-8 maturation. EMBO J. 2006;25:1895–905.

159. Le Gallo M, Paussonnier A, Blanco P, Legembre P. CD95/Fas, non-apoptotic signaling pathways, and kinases. Front Immunol. 2017;8. https://doi.org/10.3389/fimmu.2017.01216.

160. Siegel RM, Chan FKM, Chun HJ, Lenardo MJ. The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nat Immunol. 2000;1:469–74.

161. Siegel RM, Chan FKM, Chun HJ, Lenardo MJ. The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nat Immunol. 2000;1:469–74.

162. Brunner T, Wasem C, Torgler R, Cima I, Jakob S, Corazza N. Fas (CD95/Apo-1) expression regulates survival of neoplastic cells to anti-Fas antibody-induced apoptosis. Cell Biol. 2001;2:917–23.

163. Alderson MR, Tough TW, Davis-Smith T, Bradby S, Falk B, Schooley KA, et al. Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med. 1995;181:171–7.

164. Hahne M, Renno T, Schroeter M, Immler M, French L, Borman T, et al. Activated B cells express functional Fas ligand. Eur J Immunol. 1996;26:721–76.

165. Mariani SM, Krammer PH. Differential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage. Eur J Immunol. 1998;28:973–82.

166. Tinhofer I, Marschitz I, Kos M, Henn T, Egle A, Villunger A, et al. Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) Ligand+ tumor cells in B chronic lymphocytic leukemia. Blood. 1998;91:4273–81.

167. Hsu AP, Dowdell KC, Davis J, Niemela JE, Anderson SM, Shaw PA, et al. Autoimmune lymphoproliferative syndrome due to FAS mutations outside the signal-transducing death domain: molecular mechanisms and clinical pene-

168. Reilly LA, Bouillet P. What do we know about the Fas ligand. Cell Death and Disease. 2020;11:627.

169. Tinhofer I, Marschitz I, Kos M, Henn T, Egle A, Villunger A, et al. Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) Ligand+ tumor cells in B chronic lymphocytic leukemia. Blood. 1998;91:4273–81.

170. Tinhofer I, Marschitz I, Kos M, Henn T, Egle A, Villunger A, et al. Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) Ligand+ tumor cells in B chronic lymphocytic leukemia. Blood. 1998;91:4273–81.

171. Paulsen M, Janssen O. Pro- and anti-apoptotic CD95 signaling in T cells. Cell Death and Disease. 2020;11:627.

172. Hahne M, Renno T, Schroeter M, Immler M, French L, Borman T, et al. Activated B cells express functional Fas ligand. Eur J Immunol. 1996;26:721–76.

173. Paulsen M, Janssen O. Pro- and anti-apoptotic CD95 signaling in T cells. Cell Death and Disease. 2020;11:627.

174. Hahne M, Renno T, Schroeter M, Immler M, French L, Borman T, et al. Activated B cells express functional Fas ligand. Eur J Immunol. 1996;26:721–76.
Yonehara S, Ishii A, Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to
Trauth BC, Klas C, Peters AMJ, Matzku S, Möller P, Falk W, et al. Monoclonal
Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima SI, Sameshima M, et al. The
Oehm A, Behrmann I, Falk W, Pawlita M, Maier G, Klas C, et al. Puri
Kakinuma C, Takagaki K, Yatomi T, Nakamura N, Nagata S, Uemura A, et al. Acute
Cell Death and Disease          (2022) 13:248
Perry D, Sang A, Yin Y, Zheng Y-Y, Morel L. Murine models of systemic lupus
Pascual V, Farkas L, Banchereau J. Systemic lupus erythematosus: all roads lead
cell-killing factor. J Exp Med. 1989;169:1747
Factor. J Exp Med. 1989;245:301
induction of apoptosis. Science. 1989–56.

215. Trauth BC, Klas C, Peters AMJ, Matzku S, Möller P, Falk W, et al. Monoclonal
216. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima SI, Sameshima M, et al. The
217. Oehm A, Behrmann I, Falk W, Pawlita M, Maier G, Klas C, et al. Puri
218. Kakinuma C, Takagaki K, Yatomi T, Nakamura N, Nagata S, Uemura A, et al. Acute
219. Oehm A, Behrmann I, Falk W, Pawlita M, Maier G, Klas C, et al. Puri
220. Kondo T, Suda T, Fukuyama H, Adachi M, Nagata S. Essential roles in the Fas
221. Richards DM, Merz C, Gieffers C, Krendyakov A. CD95L and anti-tumor immune
222. Kurooka M, Nuovo GJ, Caligiuri MA, Nabel GJ. Cellular localization and function
223. Mitsuides N, Poulaki V, Mastorakos G, Tseleni-Balafouta S, Rotoula V, Koutras DA, et al. Fas ligand expression in thyroid carcinomas: a potential mechanism of immune evasion. J Clin Endocrinol Metab. 1999;84:2924–32.
224. Walker PR, Saas P, Dietrich PY. Role of Fas ligand (CD95L) in immune escape: the
tumor cell strikes back. J Immunol. 1997;158:4521–4.
225. Hayeh M, Rimondi Z, Schröter M, Romero P, Schreier M, French LE, et al. Mel-
226. Shiraki K, Tusi N, Shioda T, Iselbacher KJ, Takahashi H. Expression of Fas ligand in
227. Gaisman BR, Atarashi Y, Reichert TE, Saito T, Balkir L, Rabinovich H, et al. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res. 1999;59: 5356–6.
228. Moers C, Warksulat U, Even J, Niederacher D, Beckmann MW, Müchscher M. CD95 ligand expression as a mechanism of immune escape in breast cancer. Immunology. 2000;99:69–77.
229. Motz GT, Santoro SP, Wang LP, Garrabrant T, Lastra RR, Hagemann IS, et al. Tumor endothelium Fasl establishes a selective immune barrier promoting tolerance in tumors. Nat Med. 2014;20:607–15.
230. Zhu J, Powsis De Tenbossche GG, Cané S, Colalu D, Van Baren N, Lurquin C, et al. Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes. Nat Commun. 2017;8:1–11.
231. Andrade LA, Rivoltini L, Castelli C, Huber V, Perego P, Dego P, et al. Induction of lymphocyte apoptosis by tumor cell secretion of Fasl-bearing microvesicles. J Exp Med. 2002;195:1303–16.
232. Abusamra AJ, Zhong Z, Zheng X, Li M, Ichim TE, Chin JL, et al. Tumor exosomes expressing Fas ligand mediate CD8+ T-cell apoptosis. Blood Mol Dis. 2005;35:169–73.
233. Wieckowski EM, Visus C, Sajniki M, Szczepanski MJ, Storkus WJ, Whiteside TL. Tumor-derived microvesicles promote regulatory T cell expansion and induce apoptosis in tumor-reactive activated CD8+ T lymphocytes. J Immunol. 2009;183:3720–30.
234. Taghikhani A, Farzaneh F, Sharifzad F, Mardpour S, Ebrahimi M, Hassan ZM. Engineered tumor-derived extracellular vesicles: potentials in cancer immu
235. De La Motte Rouge T, Corbois J, Cauchois A, Le Boulch M, Poupon C, Henno S, et al. Inhibitors of immune checkpoints — bispeciﬁc antibodies to PD-1 and CTLa4: doubling down on T cells to decouple efﬁcacy from toxicity. Cancer Discov. 2021;11:1008–27.
236. Burton EM, Tawbi HA. Bispeciﬁc antibodies to PD-1 and CTLA4: doubling down on T cells to decouple efﬁcacy from toxicity. Cancer Discov. 2021;11:1008–10.
237. Berraondo P, Sanmamed MF, Ochoa MC, Etxeberia I, Aznar MA, Pérez-Gracia JL, et al. Cytokines in clinical cancer immunotherapy. Br J Cancer. 2018;120:16–5.
238. Chavez ARDV, Buchser W, Basse PH, Liang X, Appleman LJ, Maranché JK, et al. Pharmacologic administration of interleukin-2. Ann NY Acad Sci. 2009;1182:14–27.
239. Skrombolas D, Frelinger JG. Challenges and developing solutions for increasing the beneﬁts of IL-2 treatment in tumor therapy. Expert Rev Clin Immunol. 2014;10:207–17.
240. Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of immunotherapy for the treatment of cancer: update and overview. J Immunother. 2015;38:1–12.
241. D’Souza SD, Bonetti B, Balasingam V, Cashman NR, Barker PA, Troutt AB, et al. A survey of 90 patients with autoimmune lymphoproliferative syndrome related to TNFRSF6 mutation. Blood. 2011;118:4978–80.
242. J Clin Oncol. 2015;33:2092.
243. Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of immunotherapy for the treatment of cancer: update and overview. J Immunother. 2015;38:1–12.
244. Xue D, Hsu E, Fu Y-X, Peng H. Next-generation cytokines for cancer immu
245. Souza SD, Bonetti B, Balasingam V, Cashman NR, Barker PA, Troutt AB, et al. Inhibitors of immune checkpoints — bispeciﬁc antibodies to PD-1 and CTLa4: doubling down on T cells to decouple efﬁcacy from toxicity. Cancer Discov. 2021;11:1008–27.
246. Burton EM, Tawbi HA. Bispeciﬁc antibodies to PD-1 and CTLA4: doubling down on T cells to decouple efﬁcacy from toxicity. Cancer Discov. 2021;11:1008–10.
247. Berraondo P, Sanmamed MF, Ochoa MC, Etxeberia I, Aznar MA, Pérez-Gracia JL, et al. Cytokines in clinical cancer immunotherapy. Br J Cancer. 2018;120:16–5.
248. Chavez ARDV, Buchser W, Basse PH, Liang X, Appleman LJ, Maranché JK, et al. Pharmacologic administration of interleukin-2. Ann NY Acad Sci. 2009;1182:14–27.
249. Skrombolas D, Frelinger JG. Challenges and developing solutions for increasing the beneﬁts of IL-2 treatment in tumor therapy. Expert Rev Clin Immunol. 2014;10:207–17.
250. Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of immunotherapy for the treatment of cancer: update and overview. J Immunother. 2015;38:1–12.
251. D’Souza SD, Bonetti B, Balasingam V, Cashman NR, Barker PA, Troutt AB, et al. A survey of 90 patients with autoimmune lymphoproliferative syndrome related to TNFRSF6 mutation. Blood. 2011;118:4978–80.
252. J Clin Oncol. 2015;33:2092.
253. Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of immunotherapy for the treatment of cancer: update and overview. J Immunother. 2015;38:1–12.
Jung G, Grosse-Hovest L, Krammer PH, Rammensee HG. Target cell-restricted triggering of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med. 1996;2:574–7.

Müller M, Wilder S, Bannasch D, Israeli D, Lehlbach K, Li-Weber M, et al. p53 suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 1994;9:179-805.

McSweeney KM, Bozza WP, Alterovitz W-L, Zhang B. Transcriptomic profiling reveals p53 as a key regulator of doxorubicin-induced cardiotoxicity. Cell Death Dis. 2018;9:11:1-11.

Li J, Wang P, Long NA, Zhaung J, Springer DA, Zou J, et al. p53 prevents doxorubicin cardiotoxicity independently of its prototypical tumor suppressor activities. Proc Natl Acad Sci. 2019;116:926-34.

Van Dalen E, Caron HN, Dickinson HO, Kremer LCM. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev. 2008;1:CD005334.

Sacco G, Bigioni M, Evangelista S, Goso C, Manzini S, Maggi CA. Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin cardiotoxicity independently of its prototypical tumor suppressor activities. Proc Natl Acad Sci. 2019;116:926-34.

Calabria PJ, Bilusic M. Cancer vaccines. Hematol Oncol Clin North Am. 2006;20:2554–62.

Todorovska V, Siegel ER, Kaufmann Y, Kumarapeli A, Owen A, Wei JY, et al. Dantrolene attenuates cardiotoxicity of doxorubicin without reducing its anti-tumor efficacy in a breast cancer model. Transl Oncol. 2020;13:471–80.

Li S, Li R, Qian J, Sun J, Li G, Shen J, et al. Combination therapy of doxorubicin and quercetin on multidrug-resistant breast cancer cells and their sequential delivery by reduction-sensitive hyaluronic acid-based conjugate-d/a-Tocopheryl Poly(ethylene glycol) 1000 Succinate Mixte Micelles. Mol Pharm. 2017;10:1471-152.

Kalyan N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Donan A, et al. Protective effects of carevidol against anthracine-induced cardiomyopathy. J Am Coll Cardiol. 2006;48:2258–62.

Todorova VK, Siegel ER, Kaufmann Y, Kumarapeli A, Owen A, Wei JY, et al. Dantrolene attenuates cardiotoxicity of doxorubicin without reducing its anti-tumor efficacy in a breast cancer model. Transl Oncol. 2020;13:471–80.

Li S, Li R, Qian J, Sun J, Li G, Shen J, et al. Combination therapy of doxorubicin and quercetin on multidrug-resistant breast cancer cells and their sequential delivery by reduction-sensitive hyaluronic acid-based conjugate-d/a-Tocopheryl Poly(ethylene glycol) 1000 Succinate Mixte Micelles. Mol Pharm. 2017;10:1471-152.

Kalyan N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Donan A, et al. Protective effects of carevidol against anthracine-induced cardiomyopathy. J Am Coll Cardiol. 2006;48:2258–62.

Orbach A, Rachmilyewitz J, Parnas M, Huang JH, Tykociński ML, Dranitzki-Elhalal M. CTLA-4. Fasl induces early apoptosis of activated T cells by interfering with anti-apoptotic signals. J Immunol. 2007;179:2787–94.

Orbach A, Rachmilyewitz J, Shani N, Isenberg Y, Parnas M, Huang JH, et al. CD40-Fasl and CTLA-4-Fasl fusion proteins induce apoptosis in malignant cell lines by dual signaling. Am J Pathol. 2010;177:3159–68.

Huang JH, Tykociński ML. CTLA-4-Fasl ligand functions as a trans signal converter protein in bridging antigen-presenting cells and T cells. Int Immunol. 2001;13:529–39.

Ho MY, Sun GH, Leu SJ, KA SM, Tang SJ, Sun KH. Combination of Fas and GM-CSF confers synergistic antitumor immunity in an in vivo model of the murine Lewis lung carcinoma. Int J Cancer. 2009;2008:123-33.

Bajic D, Chester K, Neri D. An antibody-tumor necrosis factor fusion protein that inhibits lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors. J Neurol Oncol. 1996;27:133–40.

Kumar A, Watkins R, Vigeljen AE. Cell therapy with TILs: training and taming T cells to fight cancer. Front Immunol. 2021;12. https://doi.org/10.3389/FIMMU.2021.609499.

Chacon JA, Pilon-Thoms S, Sarnaik AA, Radvanyi LG. Continuous 4-1BB co-stimulatory signals for the optimal expansion of tumor-infiltrating lymphocytes for adoptive T-cell therapy. Oncoimmunology. 2013;2. https://doi.org/10.4161/ONCI.25581.

Chacon JA, Sarnaik AA, Pilon-Thoms S, Radvanyi L. Triggering co-stimulation directly in melanoma tumor fragments drives CD8+ tumor-infiltrating lymphocyte expansion with improved effector-memory properties. Oncoimmunology. 2015;4. https://doi.org/10.2147/OI.S61402.

Tschumi BO, Dumauthioz N, Marti B, Zhang L, Schneider P, Mach JP, et al. CART cells are prone to Fas- and DR5-mediated cell death. J Immunother Cancer. 2018;6:1–9.

Wagner SC, Ichim TE, Bogin V, Min WP, Silva F, Patel AN, et al. Induction and characterization of anti-tumor endothelium immunity elicited by ValloVax therapeutic cancer vaccine. Oncotarget. 2017;8:38559–613.

Tschumi BO, Dumauthioz N, Marti B, Zhang L, Schneider P, Mach JP, et al. CART cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy. J Clin Invest. 2019;129:1551–65.

Upadhayay R, Boisclair JA, Pansulaia SV, Svensson-Arvelund J, Lin MJ, Wroblewski A, et al. A critical role for fas-mediated off-target tumor killing in t-cell immunotherapy. Cancer Discov. 2021;11:599–613.

Tritz R, Hickey MJ, Lin AH, Hadwiger P, Sah DW, Neuwelt EA, et al. FAP2 gene downregulation increases tumor cell sensitivity to Fas-induced apoptosis. Biochem Biophys Res Commun. 2009;383:167–71.

Tritz R, Mueller BM, Hickey MJ, Lin AH, Hadwiger P, Sah DW, Neuwelt EA, et al. siRNA down-regulation of the PATZ1 gene in human glioma cells increases their sensitivity to apoptotic stimuli. Cancer Ther. 2008;6:865–76.

Sagiv JY, Michaeli J, Assi S, Mishalain I, Kisos H, Levy L, et al. Phenotypic diversity and plasticity in circulating neutrophil subpopulations in cancer. Cell Rep. 2015;10:562-73.

Cui C, Chakraborty K, Tang XA, Zhou G, Schoenfeldt KQ, Becker KM, et al. Neurotrophin elastase selectively kills cancer cells and attenuates tumorigenesis. Cell. 2015;164:163–77.e21.

Tiritse R, Hickey MJ, Lin AH, Hadwiger P, Sah DW, Neuwelt EA, et al. FAP2 gene downregulation increases tumor cell sensitivity to Fas-induced apoptosis. Biochem Biophys Res Commun. 2009;383:167–71.

Coudert JD, Held W. The role of the NGK2G receptor for tumor immunity. Semin Cancer Biol. 2016;63:33-43.

Jakir A, Andreachak JC, Discher DE. Macrophage checkpoints: blockade from initial clinical trials, binding analyses, and CD47-SIRPα structure–function. Antib Ther. 2020;3:80.

Arnoni A, Arnoni S, Prigozhina TB, Tzdaka K, Shen R, Grimmann L, et al. Highly efficient, In-vivo Fas-mediated apoptosis of B-cell lymphoma by hexameric CTLA4-Fasl. J Hematol Oncol. 2014;7:1-15.

Arnoni A, Ben Gigi-Tamir L, Maksidi E, Arnoni S, Ben David S, Avraham O, et al. CTLA4-Fasl, the hexameric targeted Fasl fusion protein, as potential novel treatment for DBLCL. Blood. 2017;130:4107.

Daburina S, Devaud C, Costet P, Morello A, Garrigue-Antar L, Maillasson M, et al. Functional characterization of a chimeric soluble fas ligand polymer with in vivo anti-tumor activity. PLoS ONE. 2013;8:e54000.

Taupin JL, Miossec V, Pitard B, Tzdaka K, Shen R, Grimmann L, et al. Highly efficient, In-vivo Fas-mediated apoptosis of B-cell lymphoma by hexameric CTLA4-Fasl. J Hematol Oncol. 2014;7:1-15.

Arnoni A, Ben Gigi-Tamir L, Maksidi E, Arnoni S, Ben David S, Avraham O, et al. CTLA4-Fasl, the hexameric targeted Fasl fusion protein, as potential novel treatment for DBLCL. Blood. 2017;130:4107.

Arnoni A, Ben Gigi-Tamir L, Maksidi E, Arnoni S, Ben David S, Avraham O, et al. CTLA4-Fasl, the hexameric targeted Fasl fusion protein, as potential novel treatment for DBLCL. Blood. 2017;130:4107.

Arnoni A, Arnoni S, Prigozhina TB, Tzdaka K, Shen R, Grimmann L, et al. Highly efficient, In-vivo Fas-mediated apoptosis of B-cell lymphoma by hexameric CTLA4-Fasl. J Hematol Oncol. 2014;7:1-15.

Arnoni A, Ben Gigi-Tamir L, Maksidi E, Arnoni S, Ben David S, Avraham O, et al. CTLA4-Fasl, the hexameric targeted Fasl fusion protein, as potential novel treatment for DBLCL. Blood. 2017;130:4107.
Dastagir A, Healy BC, Chua AS, Chitnis T, Weiner HL, Bakshi R, et al. Brain and Cencioni MT, Santini S, Ruocco G, Borsellino G, De Bardi M, Grasso MG, et al. DNA methylation and apoptosis. Mol Cell Death and Disease (2022) 13:248

Farrukh, Zhou Y, Jin L, Xu Y, Zhang J, Chen H, et al. CpG2 hypermethylation in Kruszewski AM, Rao G, Tatomir A, Hewes D, Tegla CA, Cudrici CD, et al. RGC-32 Yang J, Chu Y, Yang X, Gao D, Zhu L, Yang X, et al. Th17 and natural Treg cell Croft M, Siegel RM. Beyond TNF: TNF superfamily cytokines as targets for Zhong W, Jiang Y, Ma H, Wu J, Jiang Z, Zhao L. Elevated levels of CCR6 Tatomir A, Talpos-Caia A, Anselmo F, Kruszewski AM, Boodhoo D, Rus V, et al. The complement system as a biomarker of disease activity and response to treatment in multiple sclerosis. Immol Res. 2017;65:1103. Hewes D, Tatomir A, Kruzewski AM, Rao G, Tegla CA, Cudrici CD, et al. RGC-32 as a potential biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis. Exp Mol Pathol. 2015;99:498–505. Tatomir A, Talpos-Caia A, Anselmo F, Kruzewski AM, Boodhoo D, Rus V, et al. The complement system as a biomarker of disease activity and response to treatment in multiple sclerosis. Immol Res. 2017;65:1103.

Hewes D, Tatomir A, Kruzewski AM, Rao G, Tegla CA, Cudrici CD, et al. SIRT1 is decreased in relapses during patients with multiple sclerosis. Exp Mol Pathol. 2014;96:139–48.

Kruszewski AM, Rao G, Tatomir A, Hewes D, Tegla CA, Cudrici CD, et al. RGC-32 as a potential biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis. Exp Mol Pathol. 2015;99:498–505.

Tatomir A, Talpos-Caia A, Anselmo F, Kruzewski AM, Boodhoo D, Rus V, et al. The complement system as a biomarker of disease activity and response to treatment in multiple sclerosis. Immol Res. 2017;65:1103.

Hewes D, Tatomir A, Kruzewski AM, Rao G, Tegla CA, Cudrici CD, et al. SIRT1 as a potential biomarker of response to treatment with glatiramer acetate in multiple sclerosis. Exp Mol Pathol. 2017;102:191–7.

Zhong W, Jiang Y, Ma H, Wu J, Jiang Z, Zhao L. Elevated levels of CCR6+ T helper 22 cells correlate with skin and renal impairment in systemic lupus erythematosus. Sci Rep. 2017;7:1–11. 2017 7.1

Kim SJ, Lee K, Diamond B. Follicular helper T cells in systemic lupus erythematous. Front Immunol. 2018;8:1793.

Yoshitomi H, Ueno H. Shared and distinct roles of T peripheral helper and T regulatory cells in multiple sclerosis. Exp Mol Pathol. 2017;102:191–7.

Zhong W, Jiang Y, Ma H, Wu J, Jiang Z, Zhao L. Elevated levels of CCR6+ T helper 22 cells correlate with skin and renal impairment in systemic lupus erythematosus. Sci Rep. 2017;7:1–11. 2017 7.1

Steinman L. A brief history of TH17, the first major revision in the T H1/TTH2 hypothesis of T-cell-mediated tissue damage. Nat Med. 2007;13:139–45.

Langrish CL, Chen Y, Blumenstein WM, Mattson J, Basham B, Sedgwick JD, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005;201:233–40.

Yang J, Chu Y, Yang X, Gao D, Zhu L, Yang X, et al. Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum. 2009;60:1472–83.

Cenciioni MT, Santini S, Ruocco G, Borsellino G, De Bardi M, Grasso MG, et al. FAS-ligand regulates differential activation-induced cell death of human T-helper 1 and 17 cells in healthy donors and multiple sclerosis patients. Cell Mol Immunol. 2015;12:167–74.

Bettelli E, Oukka M, Kuchroo VK. TH-17 cells in the circle of immunity and autoimmunity. Nat Immunol. 2007;8:345–50.

Steinman L. A brief history of TH17, the first major revision in the T H1/TTH2 hypothesis of T-cell-mediated tissue damage. Nat Med. 2007;13:139–45.

Langrish CL, Chen Y, Blumenstein WM, Mattson J, Basham B, Sedgwick JD, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005;201:233–40.

Yang J, Chu Y, Yang X, Gao D, Zhu L, Yang X, et al. Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum. 2009;60:1472–83.

Cenciioni MT, Santini S, Ruocco G, Borsellino G, De Bardi M, Grasso MG, et al. FAS-ligand regulates differential activation-induced cell death of human T-helper 1 and 17 cells in healthy donors and multiple sclerosis patients. Cell Mol Immunol. 2015;12:167–74.

Bettelli E, Oukka M, Kuchroo VK. TH-17 cells in the circle of immunity and autoimmunity. Nat Immunol. 2007;8:345–50.

Steinman L. A brief history of TH17, the first major revision in the T H1/TTH2 hypothesis of T-cell-mediated tissue damage. Nat Med. 2007;13:139–45.

Langrish CL, Chen Y, Blumenstein WM, Mattson J, Basham B, Sedgwick JD, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005;201:233–40.

Yang J, Chu Y, Yang X, Gao D, Zhu L, Yang X, et al. Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum. 2009;60:1472–83.

Cenciioni MT, Santini S, Ruocco G, Borsellino G, De Bardi M, Grasso MG, et al. FAS-ligand regulates differential activation-induced cell death of human T-helper 1 and 17 cells in healthy donors and multiple sclerosis patients. Cell Mol Immunol. 2015;12:167–74.

Bettelli E, Oukka M, Kuchroo VK. TH-17 cells in the circle of immunity and autoimmunity. Nat Immunol. 2007;8:345–50.

Steinman L. A brief history of TH17, the first major revision in the T H1/TTH2 hypothesis of T-cell-mediated tissue damage. Nat Med. 2007;13:139–45.

Langrish CL, Chen Y, Blumenstein WM, Mattson J, Basham B, Sedgwick JD, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005;201:233–40.

Yang J, Chu Y, Yang X, Gao D, Zhu L, Yang X, et al. Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum. 2009;60:1472–83.

Cenciioni MT, Santini S, Ruocco G, Borsellino G, De Bardi M, Grasso MG, et al. FAS-ligand regulates differential activation-induced cell death of human T-helper 1 and 17 cells in healthy donors and multiple sclerosis patients. Cell Mol Immunol. 2015;12:167–74.

Bettelli E, Oukka M, Kuchroo VK. TH-17 cells in the circle of immunity and autoimmunity. Nat Immunol. 2007;8:345–50.

Steinman L. A brief history of TH17, the first major revision in the T H1/TTH2 hypothesis of T-cell-mediated tissue damage. Nat Med. 2007;13:139–45.

Langrish CL, Chen Y, Blumenstein WM, Mattson J, Basham B, Sedgwick JD, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005;201:233–40.

Yang J, Chu Y, Yang X, Gao D, Zhu L, Yang X, et al. Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum. 2009;60:1472–83.

Cenciioni MT, Santini S, Ruocco G, Borsellino G, De Bardi M, Grasso MG, et al. FAS-ligand regulates differential activation-induced cell death of human T-helper 1 and 17 cells in healthy donors and multiple sclerosis patients. Cell Mol Immunol. 2015;12:167–74.

Bettelli E, Oukka M, Kuchroo VK. TH-17 cells in the circle of immunity and autoimmunity. Nat Immunol. 2007;8:345–50.
syndromes with severe impairment of hematopoiesis. Oncotarget. 2016;7:14898–911.
349. Boch T, Luft T, Metzgeroth G, Massner M, Jann JC, Nowak D, et al. Safety and efficacy of the CD95-ligand inhibitor ansuenceret in transfusion-dependent patients with low and intermediate risk MDS. Leuk Res. 2018;68:62–9.
350. Obungu VH, Gelfanova V, Rathnachalam D, Bailey A, Sloan-Lancaster J, Huang L. Determination of the mechanism of action of Anti-Fas antibody by epitope mapping and homology modeling. Biochemistry. 2009;48:7251–60.
351. Nalivaiako K, Hofmann M, Kober K, Techwweyde N, Krammer PH, Rammensee HG, et al. A Recombinant bispecific CD20xCD95 antibody with superior activity against normal and malignant B-cells. Mol Ther. 2016;24:298–305.
352. Aceto N, Sausgruber N, Brinkhaus H, Gaidatzis D, Martiny-Baron G, Mazzolor G, et al. Tyrosine-phosphorylated SH2PR2 promotes breast cancer progression and tumor-maintaining-initiator cells via activation of key transcription factors and a positive feedback signaling loop. Nat Med. 2012;18:529–37.
353. Longley DB, Allen WL, McDermott U, Wilson TR, Latief T, Boyer J, et al. The role of Fas ligand in the joint tissue of patients with rheumatoid arthritis and osteoarthritis. Arthritis Rheum. 1991;34:1617–27.
354. Jeong D, Kim HS, Kim HY, Kang MJ, Jung H, Oh Y, et al. Soluble Fas ligand in the joint fluid of patients with osteoarthritis. J Rheumatol. 2001;28:2375–82.
355. Martin-Villalba A, Hahne M, Kleber S, Zuliani C, Stieltjes B, Metzger C, et al. Neurulation of CD95 ligand promotes regeneration and functional recovery after spinal cord injury. Nat Med. 2004;10:389–96.
356. Omokaro SO, Desierto MJ, Eckhaus MA, Ellison FM, Chen J, Young NS. Lymphocytes with aberrant expression of Fas or Fas-ligand attenuate immune brain Morrow failure in a mouse model. J Immunol. 2009;182:3414.
357. Faddei B, Thorpe CJ, Creasy C, Kale C, Robinson J, et al. Manipulating their recruitment to the in...ecting lymphocytes for adoptive cell therapy. Clin Cancer Res. 2015;21:611–21.
358. Teodorczyk M, Kleber S, Wollny D, Sefrin JP, Aytub K, Mateos A, et al. CD95 promotes metastatic spread via Sdc in pancreatic ductal adenocarcinoma. Cell Death Differ. 2015;22:1192–202.
359. Ren J, Zhang X, Liu X, Fang Z, Jiang S, June CH, et al. A versatile system for rapid multiparameter genome-scale CAR T cell generation. Oncotarget. 2017;8:17002–11.
360. Atsuta I, Liu S, Miura Y, Akiyama K, Chen C, An Y, et al. Mesenchymal stem cells inhibit multiple myeloma cells via the Fas/Fas ligand pathway. Stem Cell Res Ther. 2013;4:111.
361. Chacon JA, Sarnaik AA, Chen JQ, Creasy C, Kale C, Robinson J, et al. Manipulating their recruitment to the in...ecting lymphocytes for adoptive cell therapy. Clin Cancer Res. 2015;21:611–21.
362. Gori JL, Hsu PD, Maeder ML, Shen S, Welstead GG, Bumcrot D. Delivery and tumour-maintaining-initiator cells via activation of key transcription factors and a positive feedback signaling loop. Nat Med. 2012;18:529–37.
regrowth and functional recovery after spinal cord injury. PLoS ONE. 2014;9:e93179.

443. Boisguérin P, Covinhes A, Gallot L, Barrère C, Vincent A, Busson M, et al. A novel therapeutic peptide targeting myocardial reperfusion injury. Cardiovasc Res. 2020;116:633–44.

444. Slesarev VI, Ellithorpe R, Dimitroff T. Inhibition of systemic TNF-alpha cytotoxicity in cancer patients by D-peptidoglycan. Med Oncol. 1998;15:37–43.

445. Suda T, Nagata S. Purification and characterization of the Fas-ligand that induces apoptosis. J Exp Med. 1994;179:873–9.

446. Song E, Lee SK, Wang J, Ince N, Ouyang N, Min J, et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med. 2003;9:347–51.

447. Lasham A, Lindridge E, Rudert F, Ornust R, Watson J. Regulation of the human Fas promoter by YB-1, Puralpha and AP-1 transcription factors. Gene. 2000;252:1–13.

448. Lasham A, Moloney S, Hale T, Horner C, Zhang YF, Murison JG, et al. The Y-box-binding protein, YB1, is a potential negative regulator of the p53 tumor suppressor. J Biol Chem. 2003;278:35516–23.

ACKNOWLEDGEMENTS
Figures 1–3 made use of graphic elements modified from the Servier Medical Art website (http://smart.servier.com/), licensed under a Creative Common Attribution 3.0 Generic License (https://creativecommons.org/licenses/by/3.0/).

AUTHOR CONTRIBUTIONS
Conceptualization, VR and MLG; Wrote the original draft, collected the literature VR; Writing—review and editing MLG and EL.

FUNDING
This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 777995, from ANR (FASILE), ARC (PJA20181207700), Fondation de France and association La Vannetaise.

COMPETING INTERESTS
The authors declare no competing interests.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41419-022-04688-x.

Correspondence and requests for materials should be addressed to Matthieu Le Gallo.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022